| ID |
TITLE |
TYPE |
DATE |
TIME |
| Posters 167-178 |
COVID Featured Poster Session | COVID Featured Poster Session | 2/26/22 | 12:00 pm - 1:00 pm |
| Posters 485 - 489 |
IgE-mediated Reactions and Anaphylaxis : Novel Mechanisms and Strategies for Therapeutic Intervention | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 480 - 484 |
Inflammatory Signature of Chronic Rhinitis with Nasal Polyps | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 475 - 479 |
HealthCare Disparities in Allergy/Immunology | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 470 - 474 |
Inflammatory Response in Eosinophilic Esophagitis | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 465 - 469 |
Modulators of Environmental Allergen Burden | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 460 - 464 |
Top Topics in Basic and Clinical Immunology | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 455 - 459 |
Novel Management Options | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| Posters 450 - 454 |
ADDA Highlights of 2022 | Featured Poster Session | 2/27/22 | 4:45 pm - 6:15 pm |
| AAAAI Business Meeting | Committee & Assembly Meetings | 2/28/22 | 12:30 pm - 1:30 pm |
| RSL Governors Meeting | Committee & Assembly Meetings | 2/26/22 | 2:00 pm - 3:15 pm |
| Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma | Non-CME Educational Program | 2/28/22 | 6:30 am - 8:00 am |
| Clinical Perspectives on an Oral Prophylactic Therapy for HAE: A Case-Based Approach | Non-CME Educational Program | 2/28/22 | 6:30 am - 7:30 am |
| TEZSPIRE: A New Approach | Non-CME Educational Program | 2/27/22 | 8:30 pm - 10:30 pm |
| Component Resolved Diagnostics - Crack the code on the diagnostic dilemma | Non-CME Educational Program | 2/27/22 | 6:30 pm - 8:30 pm |
| Call-a-Colleague™ - Answering the Call: Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema | Non-CME Educational Program | 2/27/22 | 6:30 pm - 8:30 pm |
| Chronic Spontaneous Urticaria: Exploring the Potential Role of Type 2 Inflammation in Disease Pathogenesis | Non-CME Educational Program | 2/27/22 | 6:30 pm - 8:30 pm |
| A Proven Approach to Targeting Eosinophils in Severe Asthma | Non-CME Educational Program | 2/27/22 | 6:30 pm - 8:30 pm |
| Exploring Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Diagnostic Best Practices and Considerations in Addressing Underlying Inflammation | Non-CME Educational Program | 2/27/22 | 6:00 am - 7:30 am |
| Inflammation and Activation: Evaluating the Role of Eosinophils Across Diseases | Non-CME Educational Program | 2/27/22 | 6:00 am - 8:00 am |
| Addressing Barriers to EoE Diagnosis and Treatment: The Role of Updated Guidelines and Novel Therapies | Non-CME Educational Program | 2/26/22 | 8:30 pm - 10:15 pm |
| The Power of Effective Prevention for Patients With Hereditary Angioedema (HAE) | Non-CME Educational Program | 2/26/22 | 6:30 pm - 8:30 pm |
| Understanding Asthma Disparities in Communities of Color and the Role of Systemic and Localized Type 2 Inflammation in Asthma | Non-CME Educational Program | 2/26/22 | 6:30 pm - 8:30 pm |
| Understanding Chronic Cough: Patient Presentation and Assessment | Non-CME Educational Program | 2/26/22 | 6:30 pm - 8:00 pm |
| Respiratory Experts Discuss a Biologic Agent and an Inhaled Therapy | Non-CME Educational Program | 2/26/22 | 6:30 pm - 8:30 pm |
| A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis | Non-CME Educational Program | 2/26/22 | 7:00 am - 8:00 am |
| Spotting the Zebra: EGPA and HES Interactive, Case-Based Learning | Non-CME Educational Program | 2/26/22 | 6:00 am - 8:00 am |
| Optimizing the Care of Patients with Moderate-to-Severe Asthma: Minimizing Asthma Exacerbations with Biologic Therapy | Non-CME Educational Program | 2/25/22 | 8:30 pm - 9:30 pm |
| Chronic Spontaneous Urticaria: How Will Emerging Therapies Impact Treatment Paradigms? | Non-CME Educational Program | 2/25/22 | 6:30 pm - 8:30 pm |
| Moving Beyond Misperceptions of Asthma Control and Stepping Towards Personalized Care | Non-CME Educational Program | 2/25/22 | 6:30 pm - 8:30 pm |
| Case Studies: Treating Children With a Peanut Allergy | Non-CME Educational Program | 2/25/22 | 6:30 pm - 8:30 pm |
| Challenging AD Expectations | Non-CME Educational Program | 2/25/22 | 6:30 pm - 8:30 pm |
| Type 2 Inflammation: An Important Perspective for Clinicians | Non-CME Educational Program | 2/25/22 | 6:45 am - 8:45 am |
| IS IT SYSTEMIC MASTOCYTOSIS? Best Practices for Diagnosis and Management | Non-CME Educational Program | 2/25/22 | 6:45 am - 8:45 am |
| Learn About A Now Approved Oral Rx Treatment for Moderate-to-Severe Atopic Dermatitis | Non-CME Educational Program | 2/24/22 | 6:30 pm - 8:30 pm |
| Disease Burden and Endophenotypes-Finding the Path Through Clinical Dilemmas in CRSwNP and SEA | Non-CME Educational Program | 2/24/22 | 6:30 pm - 8:30 pm |
| Annual Meeting Program Committee | Committee & Assembly Meetings | 2/28/22 | 10:00 am - 12:00 pm |
| AAAAI Foundation Council Meeting | Committee & Assembly Meetings | 2/28/22 | 10:00 am - 11:30 am |
| Annual Meeting Awards Committee | Committee & Assembly Meetings | 2/28/22 | 8:00 am - 9:00 am |
| Microbes in Allergy and Asthma Committee | Committee & Assembly Meetings | 2/28/22 | 7:00 am - 8:00 am |
| JACI Journals' Reviewers Forum and Reception | Committee & Assembly Meetings | 2/27/22 | 4:45 pm - 6:30 pm |
| JACI: In Practice Publisher Meeting | Committee & Assembly Meetings | 2/27/22 | 2:00 pm - 3:00 pm |
| JACI Associate Editors Meeting | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:45 pm |
| Division Directors Committee Meeting | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| Office of Medical Education Committee | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| Advocacy Committee Meeting | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| Asthma & Allergic Diseases in Older Adults Committee Meeting | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| Practice Management Committee Meeting | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| Occupational Diseases Committee | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| Cells and Mediators of Allergic Inflammation Committee | Committee & Assembly Meetings | 2/27/22 | 12:30 pm - 1:30 pm |
| JACI International Advisory Board | Committee & Assembly Meetings | 2/27/22 | 7:00 am - 8:00 am |
| Anaphylaxis Committee Meeting | Committee & Assembly Meetings | 2/27/22 | 7:00 am - 8:00 am |
| Practice, Diagnostics and Therapeutics Committee | Committee & Assembly Meetings | 2/27/22 | 7:00 am - 8:00 am |
| Program Directors Assembly Executive Committee | Committee & Assembly Meetings | 2/27/22 | 7:00 am - 8:00 am |
| Immunotherapy, Allergen Standardization & Allergy Diagnostics Committee | Committee & Assembly Meetings | 2/27/22 | 6:45 am - 8:00 am |
| Allergic Fungal Respiratory Diseases Committee | Committee & Assembly Meetings | 2/27/22 | 6:45 am - 7:45 am |
| Rhinitis, Rhinosinusitis & Ocular Allergy Committee Meeting | Committee & Assembly Meetings | 2/27/22 | 6:45 am - 7:45 am |
| Faculty Development Program Reunion Breakfast (Invitation Only) | Committee & Assembly Meetings | 2/27/22 | 6:00 am - 8:00 am |
| Continuing Certification and Professional Education Committee | Committee & Assembly Meetings | 2/26/22 | 5:00 pm - 6:00 pm |
| NAIA Business Meeting & Reception | Committee & Assembly Meetings | 2/26/22 | 4:45 pm - 6:15 pm |
| AAAAI Journals Joint Editors-in-Chief | Committee & Assembly Meetings | 2/26/22 | 2:00 pm - 3:30 pm |
| Allied Health Education Committee | Committee & Assembly Meetings | 2/26/22 | 2:00 pm - 3:00 pm |
| Committee on the Underserved Meeting | Committee & Assembly Meetings | 2/26/22 | 1:45 pm - 2:45 pm |
| Eosinophilic Gastrointestinal Disorders Committee | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Asthma, Cough, Diagnosis and Treatment Committee | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Allergic Skin Diseases Committee meeting | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Adverse Reactions to Drugs, Biologicals and Latex Committee Meeting | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Health Informatics, Technology & Education Committee Meeting | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Autoimmunity and Altered Immune Response Committee Meeting | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Core Curriculum, Education & Residency Review Subcommittee | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| Primary Immunodeficiency Committee Annual Meeting | Committee & Assembly Meetings | 2/26/22 | 12:30 pm - 1:30 pm |
| NAB Counters & Aerobiology Committee Meeting | Committee & Assembly Meetings | 2/26/22 | 12:15 pm - 1:45 pm |
| AAAAI Past Presidents & Honorary Award Recipients Luncheon | Committee & Assembly Meetings | 2/26/22 | 12:00 pm - 1:30 pm |
| Interest Section Coordinating Committee | Committee & Assembly Meetings | 2/26/22 | 10:45 am - 11:45 am |
| Associates to the AAAAI Breakfast & Business Meeting | Committee & Assembly Meetings | 2/26/22 | 9:00 am - 11:00 am |
| NAB, Allergy and Aerobiology International Consortium | Committee & Assembly Meetings | 2/26/22 | 7:00 am - 8:00 am |
| JACI: In Practice Editorial Board Meeting | Committee & Assembly Meetings | 2/26/22 | 7:00 am - 8:00 am |
| Genetics, Molecular Biology & Epidemiology Committee Meeting | Committee & Assembly Meetings | 2/26/22 | 7:00 am - 8:00 am |
| Registry/Measures Stewardship Annual Committee Meeting | Committee & Assembly Meetings | 2/26/22 | 7:00 am - 8:00 am |
| Fellows-in-Training Committee | Committee & Assembly Meetings | 2/26/22 | 7:00 am - 8:00 am |
| Adverse Reactions to Foods Committee | Committee & Assembly Meetings | 2/26/22 | 6:15 am - 7:45 am |
| Integrative Medicine Committee | Committee & Assembly Meetings | 2/25/22 | 5:30 pm - 6:30 pm |
| Vaccine Committee | Committee & Assembly Meetings | 2/25/22 | 5:30 pm - 6:30 pm |
| Allied Health Assembly Reception | Committee & Assembly Meetings | 2/25/22 | 5:15 pm - 6:30 pm |
| Quality Adherence and Outcomes Committee Meeting | Committee & Assembly Meetings | 2/25/22 | 1:00 pm - 2:00 pm |
| JACI Editorial Board Meeting | Committee & Assembly Meetings | 2/25/22 | 12:30 pm - 1:45 pm |
| Sports, Exercise & Fitness Committee | Committee & Assembly Meetings | 2/25/22 | 12:30 pm - 1:30 pm |
| Credentials Committee Meeting | Committee & Assembly Meetings | 2/25/22 | 12:30 pm - 1:30 pm |
| Office of Practice Management | Committee & Assembly Meetings | 2/25/22 | 12:30 pm - 1:30 pm |
| Program Directors Assembly (PDA) Forum and Networking Luncheon | Committee & Assembly Meetings | 2/25/22 | 12:00 pm - 1:45 pm |
| Environmental Exposure and Respiratory Health Committee | Committee & Assembly Meetings | 2/25/22 | 12:00 pm - 1:30 pm |
| Mast Cells Disorders Committee | Committee & Assembly Meetings | 2/25/22 | 12:00 pm - 1:00 pm |
| Website, Internet and Related Technologies Committee Meeting | Committee & Assembly Meetings | 2/25/22 | 12:00 pm - 1:00 pm |
| RSLAAIS Reception, Business Meeting and Forum | Committee & Assembly Meetings | 2/25/22 | 4:45 pm - 6:30 pm |
| CA76 |
Bullous Reaction Following Allergen Immunotherapy | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| L28 | A Modified Bronchodilation Test for Assessing Airway Reversibility | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L18 |
Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma. | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L13 |
Intranasal Budesonide Significantly Improves Symptoms in Subjects with Moderate-to-severe Congestion and Rhinitis Triggered/worsened by Pollution | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L32 |
Outcomes for COVID-19 Patients with Asthma at a Tertiary Care Center | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L39 |
SARS-CoV-2 surveillance in households with and without asthmatic/allergic children: The Human Epidemiology and Response to SARS-CoV-2 study (HEROS) | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L11 | The Single Cell Transcriptomic and Epigenomic Map of the Innate Immune Response to Vaccination in Lymph Nodes | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L20 |
Reduced SARS-CoV-2 Vaccine Response in Patients Treated with Biologic Therapies for Asthma and Atopic Dermatitis | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L14 |
Assessment of Training in Health Disparities (HD) in Allergy/Immunology | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L17 |
Sesame Allergy: Characteristics and Outcomes | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L29 |
Exploratory Survey Research Study of 2,000 Alpha-gal Syndrome Patients: Symptoms and Experiences in the United States? | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L30 |
The First Clinical Study of Ara h 6 Relevance in a Pediatric Peanut Allergy Population in the United States. | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L19 |
A randomized, double-blind placebo-controlled first in human study with mannan-conjugated birch pollen allergoids administered subcutaneously to allergic patients | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L38 |
Quality of Life and Improving Outcomes in Peanut Oral Immunotherapy | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L23 |
Modulation of T and B cell Responses by Virus-like particle (VLP) Expressing Peanut Allergen Ara h 2: A Novel Vaccine Candidate for Peanut Allergy | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L15 |
A Tyrosine Adsorbed Modified Grass Allergen + MPL SCIT Demonstrates Clinically Improvement in Combined Symptom and Medication Score in Subjects with Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L42 |
Differential PTGDR2 Expression In Blood Cell Populations From Asthmatic Patients After Treatment With Anti-IL5 Or Anti-IL4R | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L25 |
Asthma Severity and COVID-19 Related Hospitalizations | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L16 |
Health-related quality of life outcomes in a Phase 2b Randomized Trial evaluating the effectiveness and safety of Probiotic Peanut Oral Immunotherapy | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L35 |
Effect of house dust mite sublingual immunotherapy in IgE and IgG4 responses to Der p 1, Der p 2 and Der p 10 and IgE to S. aureus enterotoxins in patients with Atopic Dermatitis: a randomized, double-blind, placebo-controlled study | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L37 |
A Phase 1, Randomized Study Evaluating the Safety Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single Ascending Doses of Epinephrine Prodrug 109 Sublingual Film (AQST-109) in Healthy Male Volunteers | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L36 |
Peanut-Induced Food Protein Induced Enterocolitis (FPIES) | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L26 |
Tolerability of COVID-19 Vaccination in Patients with Mast Cell Activation | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L41 | The Effect of COVID-19 on The September Asthma Peak | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L21 | Exploiting CD22 on Memory B Cells to Induce Tolerance to Peanut Allergens | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L31 |
Effect Of Benralizumab On Skin Responses To Intradermal Allergen Challenge In Patients With Moderate-To-Severe Atopic Dermatitis | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L34 | HuR ablation or inhibition reduces lung inflammation and Th2 cytokine expression in mouse model of allergic asthma and in asthmatic CD4+ T cells | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L27 | Partial loss of function mutations in GINS4 lead to natural killer cell deficiency with neutropenia | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L22 | Androgen Receptor (AR) Signaling Decreases Glutamine Metabolism in Th17 Cells to Decrease House Dust Mite-induced Airway Inflammation | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L24 |
IFNG is constitutively expressed by esophagus-resident CD8+ T cells and is poised to mediate a disease-specific effect via its action on IFNGR+ eosinophils during active EoE | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| L40 |
Racial and Socioeconomic Differences in Perceived Quality of the Patient/Care Team Relationship Among Individuals with Asthma | Poster Session (LB) | 2/28/22 | 9:45 am - 10:45 am |
| CA61 |
Symptomatic Severe Combined Immunodeficiency with Heterozygous RAG1 mutation and NOD2 mutation. | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA68 |
Unveiling An Unusual Urticaria | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA11 |
Acute Manifestation of Idiopathic Nodular Panniculitis | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA03 |
Refractory IBD and relapsing HLH in an adult with XIAP deficiency | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA74 |
Hormones Gone Wild: Evaluation and Management of a Severe Case of Progestogen Hypersensitivity | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA35 |
A 12-year old male with Infantile Onset Crohn's Disease and Recurrent Skin Abscesses | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA59 | When A Vaccine is Not Enough | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA53 |
Serious Serositis in a Patient with Bruton (X-linked) Agammaglobulinemia | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA69 |
Sesame Allergy Despite Negative Commercial Skin Prick Tests | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA38 |
NCF1 Heterozygosity: A Pathological Footprint for Very Early Onset Inflammatory Bowel Disease | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA29 | Indolent Systemic Mastocytosis diagnosed in a patient with Imported Fire Anaphylaxis | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA19 |
Acute Generalized Exanthematous Pustulosis (AGEP) induced by Low-Osmolarity Contrast Media | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA67 |
Secondary functional immunodeficiency in the setting of severe malnutrition | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA08 |
Digital ischemia as a presenting feature of Hypereosinophilic Syndrome-associated vasculitis | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA06 |
IIH and Tertiary AI Associated with Inhaled Fluticasone Discontinuation in a Pediatric Patient | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA45 |
TACI-Mutant CVID Presenting as Status Epilepticus in the Setting of Autoimmune Encephalitis | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA49 |
IgG3 Antibody Response to COVID-19 Vaccination in a Patient with Large IgH Heavy Chain Deletion | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA07 |
Two Patients with Hereditary Angioedema Type 1 Infected with SARS-CoV-2 During Pregnancy | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA25 |
Cemiplimab (PD-1 inhibitor) Induced Rash and Mucositis | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA44 |
Macadamia nut allergy | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA42 |
Bell's Palsy After the Moderna and Pfizer COVID-19 Vaccines | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA41 |
Chronic Eosinophilic Pneumonia potentially misdiagnosed as Fungal Pneumonia in the Caribbean | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA18 |
SARS-CoV-2 Vaccine desensitization after anaphylactic reaction to the first dose of the vaccine | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA10 |
ECMO to Treat Refractory Hypercapnia in Status Asthmaticus | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA15 |
A case of necrotizing axillary lymphadenopathy after casarivimab-imdevimab infusion. | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA56 |
Periodic Fever: A Rare Genetic Variant associated with Autoinflammatory Disorders | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA70 | The Red Flag of Shoulder Pain in Asthma: Avascular Necrosis Revisited | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA01 |
Already on the Treatment: A Case of Insulin Hypersensitivity | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA58 |
FPIES + Anaphylaxis- When The Immune System Misbehaves in More Ways Than One | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA23 |
A Novel Case of PI4KA Variants Leading to Multiple Intestinal Atresias and Combined Immunodeficiency | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA13 |
Autoimmune Hepatitis in the Setting of Sarcoidosis: The Possible Sequelae of Anti-TNFa Therapy | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA24 |
Novel Mutation in STIM1 Leading to Combined Immunodeficiency Syndrome | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA27 |
Chronic Refractory Urticaria Treated with Sirolimus and High Dose Omalizumab | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA36 |
A Patient with WHIM Syndrome | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA55 | Pembrolizumab-induced Encephalopathy | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA34 |
Unique Disseminated Tuberculosis & Hemophagocytic Lymphohistiocytosis Reveal Rare CD40L Deficiency | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA66 |
Like Father, Like Son - A Case of Hereditary Interstitial Lung Disease | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA20 | Allergic Bronchopulmonary Mycosis in a Pediatric Patient with Primary Ciliary Dyskinesia | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA02 |
Treatment of autoimmune inner ear disease with canakinumab | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA65 |
Concomitant effects of EBV and COVID-19 infections on a patient with CVID and colitis | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA33 |
A Rare Case of Type 2 Griscelli Syndrome in association with Hemophagocytic Lymphohistiocytosis | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA71 |
The cow’s milk allergy that wasn’t: allergy to supplemental oral lactase enzyme | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA22 |
Multisystem Manifestations of Severe Common Variable Immunodeficiency | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA26 |
Activated PI3 Kinase Syndrome in a Pediatric Patient | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA47 |
Funnel Cake Anaphylaxis | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA52 |
A Case of 22q11.2 Duplication and Triplication Syndrome With Immunodeficiency and Atopy | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA12 |
A Complex Case of Multiple Drug Hypersensitivity | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA09 |
Myotonic dystrophy 1 and Hypogammaglobulinemia | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA37 |
Utility of galsulfase skin testing in the evaluation of infusion reactions | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA04 |
Alpha-gal Syndrome: Successful Meat Reintroduction and the Impact of a Repeat Tick Bite on sIgE | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA31 |
Difficult to treat recurrent viral skin infections as a manifestation of XMEN disease | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA75 | Selective allergy to common beans: a new allergen of 15 kDa. | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA05 |
Occult Presentation of Gastric Adenocarcinoma in Ataxia-Telangiectasia as a Rare Silent Malignancy | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA32 |
Novel FOXN1 variant as the cause of T-cell lymphopenia and positive SCID screening in a newborn | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA21 |
Evaluating COVID-19 sequelae in a pediatric patient | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA62 |
Mevalonate Kinase Deficiency with Recurrent Soft Tissue Swelling | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA63 |
An adolescent female with recurrent hives found to have underlying thymoma. | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA64 | Infantile Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA72 |
Recombinant Factor IX Desensitization in a Child with Hemophilia B and Factor IX Inhibitors | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA60 |
What is in a Name? CVID vs XLA | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA57 |
A Not So Common Presentation of Common Variable Immunodeficiency | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA43 |
A baby with TP63-related syndrome presenting with a T-NK+B+ SCID phenotype | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA51 |
Cutaneous Mycobacterium abscessus infection following cosmetic injection in a 24-year-old female | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA30 | A Near Miss is as Good as a Mile: Recognizing a Hypereosinophilic Syndrome in an Unlikely Setting | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA17 |
A young child with ADA-SCID and Glutaric acidemia type -1 maintained on Elapegademase | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA46 |
An SIAE variant in a 20-year-old male with recurrent sinopulmonary infections and autoimmunity | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA28 |
19 years-old-female with immune dysregulation due to inherited pathogenic RNU4ATAC variant. | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA48 |
Use of ASCENIV in a Young Male with Immune Abnormalities and Multiviral Induced Respiratory Failure | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA39 | Anti-Bile Salt Export Pump Disease | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA50 |
Granulomatous disease: Caused by or causing immunodeficiency? | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA73 | Millet: A “Gluten-free” and “healthy” cereal with the potential to induce anaphylaxis | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA54 |
Common Variable Immunodeficiency with a Novel NFKB1 Mutation Diagnosed after Complicated COVID-19 | Case Report Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| CA40 |
Recurrent Thrombocytopenia Associated with Immunoglobulin Replacement in a Patient with CVID | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA14 |
A Case Of CSF Nocardiosis with Anti-GM-CSF Antibodies | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| CA16 |
Keeping a Broad Differential Diagnosis: Pancytopenia and Inconclusive Newborn Screen for SCID | Case Report Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 001 |
Use of the severity grading system for acute allergic reactions (SGS-AR) to evaluate allergic reactions during peanut oral food challenges in a pediatric allergy center | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
1 36th Annual Harold S. Nelson Military Allergy/Immunology Symposium
In-Person Course2/24/22, 7:20am - 3:15pm
7:20 am - 3:15 pm
| 1 | 36th Annual Harold S. Nelson Military Allergy/Immunology Symposium | In-Person Course - OD | | |
| 002 |
Improving Access to Allergy/Immunology Consultation for Children with Anaphylaxis in a Pediatric Emergency Department: A Multidisciplinary Approach | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 003 |
Clinical Characteristics of Anaphylaxis Cases in an Inner-City Pediatric Emergency Department (E.D.) in Brooklyn Over a 4 Year Period | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 004 |
Atopy and Idiopathic Anaphylaxis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 005 |
Impact of COVID-19 Restrictions on Anaphylaxis Presentations to the Emergency Department | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 006 |
Subanalysis of an Open-Label, Crossover Study to Assess the Relative Bioavailability of Self-administered Nasal Epinephrine Compared to Administration by Trained Health Personnel in Healthy Adult Subjects | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 007 |
Neffy Human Factor Findings | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 008 |
Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual IM injection and Epinephrine Auto-Injectors | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 009 |
Pharmacokinetics and Pharmacodynamics of Neffy (1 mg) compared to EpiPen (0.3 mg) and Manual IM injection (0.3 mg) – an Integrated Analysis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 010 |
Accidental Intravascular Auto-Injection of Epinephrine (Adrenaline) Rapidly Increases Pharmacokinetic and Hemodynamic Parameters | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 011 |
Staphylococcus aureus-induced cytokines cause aberrant lipid compositions and skin barrier dysfunction in children with atopic dermatitis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 012 |
Transient Receptor Potential Cation Channel Subfamily V Member 1 (TRPV1) Plays a Major Role in Low Temperature-Mediated Skin Barrier Dysfunction: Potential Implications for Atopic Dermatitis and Food Allergy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 013 |
Local IL-4Ra Blockade at Sites of Allergic Skin Inflammation Dampens Inflammation and Promotes S. aureus Clearance in Mice. | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 014 |
Mast Cells are Locally Activated and Respond to MRGPRX2 Stimulation in Atopic Dermatitis Ex Vivo Skin Biopsies | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 015 | Epigenetic and Transcriptional Dysregulation in T cells of Patients with Atopic Dermatitis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 016 | Thrombin and Fibrinogen Play a Critical Role in Atopic Dermatitis Pathogenesis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 017 |
Using Nevisense Go to Identify Skin Epithelial Barrier Defect | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 018 |
Assessments of Histopathology In Skin of Patients With Allergic Asthma | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 019 | Effects of Type 1, 2, and 3 Immunity on the Viral Susceptibility of Human Keratinocytes | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 020 |
Exploring Dietary Patterns And The Distribution Of Atopic Dermatitis In A Birth Cohort Of A Metropolitan Area In Germany | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 021 |
Childhood Allergy and the NeOnatal Environment (CANOE) Research Protocol and Recruitment Redesign during the COVID-19 Pandemic | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 022 |
The Patient Burden of Moderate-to-Severe Atopic Dermatitis (AD) in Children Aged <12 Years: Results From 732 Patients in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) Observational Study | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 023 |
The Munich Atopy Prediction Study to discover patterns in the development of Type II inflammation | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 024 |
Modulations Of Natural Delivery On Yogurt-induced Reduction Of Non-specific Skin Reactivity In Healthy Infants | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 025 | Timing of Itch Among Children with Atopic Dermatitis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 026 |
A Multidisciplinary Approach Between Allergy, Immunology and Dermatology to Evaluate Patients With Severe Atopic Dermatitis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 027 |
Does Misalignment Between Social and Biological Clocks Induce Severe Atopic Dermatitis? | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 028 |
Identifying Relevant Disease Characteristics Regarding Atopic Dermatitis In Germany: A Retrospective Web Search Data Analysis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 029 |
Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 030 |
Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 031 |
Oral Difelikefalin Reduces Atopic Dermatitis–Associated Pruritus | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 032 |
Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 033 | Impact of Essential Oil Based Nasal Spray Sinusol® on Sinonasal-Related Impairment | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 034 |
iNKT cells are enriched in inflammatory infiltrates of chronic rhinosinusitis with nasal polyposis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 035 |
Nociceptor Neurons Control Pollution-exacerbated Asthma | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 036 | The Role of Endogenous Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling in Respiratory Syncytial Virus (RSV) Infection | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 037 |
Immune and Lipid Changes in Patients with a Severe Community-acquired Pneumonia | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 038 |
Upper Airway Microbiomes Respond to Preceding Air Pollution During Periods of Health and Respiratory Illness Events | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 039 |
Airborne Toxicants Induce Pro-inflammatory Cytokines in Both Patients with Asthma and with COPD | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 040 |
Airway Hyperresponsiveness and Eosinophilic Airway Inflammation In Patients With Atopic Dermatitis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 041 |
Tezepelumab Reduces Inflammatory Biomarkers as Early as Week 2 and Maintains Reductions Until Week 52 in the Phase 3 NAVIGATOR Severe Asthma Trial | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 042 |
Dupilumab Efficacy in LIBERTY ASTHMA QUEST Patients With Uncontrolled, Moderate-to-Severe Asthma By Allergen Sensitization Status | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 043 |
Reduction in Asthma Exacerbations after Treatment with Benralizumab: Results from the ZEPHYR 2 Study | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 044 |
Efficacy of Tezepelumab in Patients with Moderate-to-Severe, Uncontrolled Asthma: A Pooled Analysis of the Phase 2b PATHWAY and Phase 3 NAVIGATOR Studies | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 045 |
LONG-TERM EFFECTIVENESS AND SAFETY OF BENRALIZUMAB FOR UNCONTROLLED EOSINOPHILIC ASTHMA IN REAL-WORD PRACTICE. | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 046 |
Tezepelumab Treatment Reduced Asthma Symptomatic Days in Adults and Adolescents with Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 047 |
Omalizumab treatment is associated with improvement in outcomes in children with asthma despite pretreatment serum IgE exceeding dosing guidelines | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 048 | Patient-reported therapeutic experiences with biologic agents in aspirin-exacerbated respiratory disease | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 049 |
Biologicals In Severe asthma – Stopping The Unstoppable | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 050 |
Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarkers in Children With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 051 |
Real-World Response To Anti-Eosinophil Biologics For Severe Eosinophilic Asthma | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 052 | The Oral Eosinophil-lowering Drug Dexpramipexole Improves FEV1 Largely Thorough its Effect on FVC | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 053 |
Clinical and Economic Burden of Patients With Severe Asthma Untreated With a Biologic in the United States, Overall and by Blood Eosinophil and Level of Asthma Control | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 054 |
Long-term safety and effectiveness of mepolizumab for severe eosinophilic asthma | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 055 |
Safety and efficacy of mepolizumab at home admnistration- a portuguese experience | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 056 |
Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 057 |
Effects Of Mavorixafor On Functional Impairments Due To A Novel Missense CXCR4 Mutation In A Patient With WHIM-Like Syndrome | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 058 |
The Humoral Immune Response To SARS-CoV-2 Infection And/or Immunization in Immunocompromised Versus Immunocompetent Individuals | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 059 |
A family with forkhead box N1 (FOXN1) haploinsufficiency causing severe combined immunodeficiency (SCID) | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 060 |
Heterozygous FOXN1 variant in an Infant with severe T cell lymphopenia and thymic hypoplasia with improvement of CD4CD45RA within first year of life. | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 061 |
A Case of 22q11.21 Microduplication in Identical Twins with Variable Phenotype | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 062 |
Antibody Production After COVID-19 Immunization In Patients With Primary Immunodeficiency: A Single Center Experience. | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 063 |
Protein kinase C Delta Deficiency should be in the differential diagnosis of Chronic Granulomatous Disease | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 064 |
Demographic, Clinical and Laboratory Characteristics of Individuals With IgE Deficiency - A Single Center Experience | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 065 |
Under-recognition of Hypogammaglobulinemia in Patients with Undetectable Serum IgE | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 066 |
Clinical Variability of STAT3 GOF Amongst a Single-Family Cohort | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 067 |
IgA Deficiency: From Diagnosis to Outcomes | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 068 |
Descriptive Study of IgG Protection for PCV13 Serotypes in Immunodeficient Patients on IVIG | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 069 | Comparing Perspectives on Transition of Care for Primary Immunodeficiency Patients | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 070 |
Diagnostic and Therapeutic Challenges for Infants with Radiosensitive (RS)-SCID Identified by Newborn Screening (NBS) | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 071 |
Immunoglobulin deficiency in 22q11.2 syndrome cohort | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 072 |
Prevalence of Anti-lymphocyte Antibodies in Patients with Good Syndrome and Partial RAG Deficiency | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 073 |
Hypogammaglobulinemia Following Anti-CD20 Therapy: Retrospective Analysis of Patient Risk Factors | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 074 |
Immune Reconstitution Post CAR-T - A Role for the Immunologist in Unlocking the CAR-Key? | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 075 |
Frequency of Abnormal Immune Evaluation in Pediatric Trisomy 21 Patients with Recurrent Infections | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 076 |
Long-term Immunosuppression Associated With Disruption Of B-cell Populations And Increased Infection Risk | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 077 |
Malignancy risk in pediatric subjects with undetectable serum IgE | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 078 |
NFKB2 Mutation in 2 Siblings with DAVID Syndrome and CVID with Variable Presentations | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 079 |
Extremely low immunoglobulins in a patient with CVID phenotype and TNFRSF13B and NFKB2 variants | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 080 |
Effects Of The COVID-19 Pandemic On A Group Of Patients With Pathogenic Variant of Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) in a Tertiary Center in Florida | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 081 | New onset of autoimmune diseases in patients with primary antibody deficiency and CD4 lymphopenia after COVID-19. | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 082 |
Patient with AR-CGD Presenting with Disseminated Aspergillosis During Pregnancy Associated with Suppression of the Th17 Axis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 083 |
Diagnostic Utility of Targeted Next Generation Sequencing Panels in Inborn Errors of Immunity | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 084 | Comparison of the Airborne Fungal Spore Concentrations in the Mojave Desert and Las Vegas From 2016-2020 | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 085 | Ozone and Nitrogen Oxide enhance the Immunogenicity of Ragweed Pollen | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 086 | Exposure to Particulate Matter Increases Expression of the Angiotensin converting enzyme-2 (ACE2) Receptor | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 087 |
Impact Of Wildfire On Patients With Respiratory Allergy In An Urban Setting | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 088 | Higher fractional exhaled nitric oxide levels of children living in the semi-basement apartment (Banjiha) in South Korea: a comparison between floor level and building types | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 089 |
Occupational Asthma from Cannabis Indica Hybrids: Case Reports | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 090 |
Age and Successful Food Allergy Desensitization in Children | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 091 |
Baseline Clinical and Immunologic Characteristics of Children Screened in the Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Trial | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 092 |
Assessing Caregiver Acceptability and Perceived Barriers to Peanut Oral Immunotherapy (OIT) in the General Food Allergic Pediatric Population | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 093 |
Effectiveness of Real-World Peanut Oral Immunotherapy at a Large Tertiary Referral Academic Center | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 094 |
Milk Incorporation into Diet Influences Natural History of Milk Allergy in a Pediatric Population | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 095 |
Food allergy in adults is associated with more systemic and non-IgE mediated symptoms compared to children | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 096 |
Anaphylaxis Episodes during Peanut Oral Immunotherapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 097 |
Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 098 |
Dose-related allergic adverse events during multi-food oral immunotherapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 099 |
Outcomes of real-world use of FDA-approved peanut oral immunotherapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 100 |
Safety of Tree Nut Oral Immunotherapy in Clinical Practice | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
101 Breakthroughs in Understanding and Treating Eosinophilic Gastrointestinal Diseases (EGID): Organized by CEGIR and TIGERS
In-Person Course2/24/22, 8am - 5pm
8:00 am - 5:00 pm
| 101 | Breakthroughs in Understanding and Treating Eosinophilic Gastrointestinal Diseases (EGID): Organized by CEGIR and TIGERS | In-Person Course - OD | | |
| 101 |
Baked Egg and Baked Milk Oral Desensitization Outcomes in a Pediatric Cohort | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
102 Practical Workshops to Jumpstart Your Drug Allergy Assessments
In-Person Course2/24/22, 8am - 1:15pm
8:00 am - 1:15 pm
| 102 | Practical Workshops to Jumpstart Your Drug Allergy Assessments | In-Person Course - OD | | |
| 102 | Qualitative Evaluation of a Canadian Community Oral Immunotherapy Program | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 103 |
Quantitative assays to test for presence of cross-contamination in allergen-specific oral immunotherapy products | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 104 |
Safety of Modified Sesame Desensitization Protocols in Children in Real-World Clinical Practice | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 105 |
Preschool Multi-food Oral Immunotherapy as Safe and Effective as Single Food Therapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 106 |
Caregiver Perceptions and Lifestyle Behaviors After Completion of Peanut Immunotherapy: A Long-Term Follow-Up Study | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 107 |
Virus Like Particle (VLP) Based Peanut Allergen Immunotherapy Candidate Display A Decreased Activation And Histamine Release From CRTH2+ Basophils: A Proof of Concept Study | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 108 |
Long-term adherence and risk of allergic reactions in children who attained milk oral immunotherapy maintenance | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 109 | Baseline Characteristics of Patients Who Fail Low-Dose Challenges and Patients Who Reach Maintenance OIT to Cashew | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 110 |
Pediatric Clinicians’ Knowledge of Infant Peanut Introduction Guidelines Following iREACH Training Modules | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 111 |
Racial and Ethnic Differences in Infant Peanut Introduction Beliefs and Practices Among Parents/Caregivers in the United States | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 112 |
US Caregiver Beliefs, Attitudes, and Considerations for Early Introduction of Peanut | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 113 |
Knowledge of Early Peanut Introduction Guidelines Among Parents of Patients in a General Pediatric Clinic in an Inner-City Hospital | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 114 |
Does Peanut Introduction Set The Scene For Earlier Introduction Of Other Food Allergens During Infancy? | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 115 |
Current Peanut Introduction Practices amongst a Large, Representative Sample of US Households | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 116 |
Does Parental Food Allergy History Matter? —Assessing Awareness of NIAID-Sponsored Peanut Allergy Prevention Guidelines and Infant Feeding Practices in a Representative Sample of US Parents | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 117 | Studies on Cashew and Shrimp-Oral Immunotherapy-Induced Changes in Allergen-Reactive CD4+ T Cells | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 118 | Real-World Safety Analysis of Preschool Tree Nut and Sesame Oral Immunotherapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 119 |
Assessment of Social Limitations in Children with Peanut Allergy Undergoing Peanut Oral Immunotherapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 120 |
Effect of Allergy Specialty Care on Healthcare Utilization Among Children with Peanut Allergy in the US | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 121 |
Implementing Outpatient Penicillin Allergy Assessments by Non-Allergy Providers | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 122 | Automatic Algorithm for Quality Assessment of the Unsupervised Spirometry Based on Machine Learning Method | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 123 |
Impact of Project ECHO on Community Pediatricians’ Food Allergy Knowledge | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 124 |
Implementation of an automated prediction scoring system to identify patients at possible increased risk for Hereditary Angioedema | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 125 |
The ASTHMAXcel PRO Mobile Application’s Field Testing Results in Adult Patients: Evaluating User Characteristics, Health Literacy, App Satisfaction, and Adoption | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 126 |
Increasing SARS-CoV-2 Vaccine Counseling by Fellows in the Allergy Clinic | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 127 |
Improving Asthma Control in a Primary Care Population; A Telehealth Illness Management Program | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 128 | Using machine learning to predict fracture risk in large U.S. population: An Analysis of NHANES 2005-2014 | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 129 |
Disease Symptomology, Quality of Life (QoL), and Employment Status Among Patients with Systemic Mastocytosis (SM) | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 130 |
Development and validation of explainable machine learning prediction model for asthma exacerbations in people who stop asthma biologics | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 131 |
Developing Structured Data Entry Forms for Food Allergy Clinical Documentation in The Electronic Health Record | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 132 |
Searching for Relief: A Comparative Study Between Pollen Concentrations and Allergy-Related Search Terms | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 133 |
Developing a Toolkit for Outpatient Penicillin Allergy Assessments to Change Patient Outcomes | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 134 |
Improving Aztreonam Stewardship Through a Dedicated Penicillin Allergy Testing Pharmacist | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 135 |
Penicillin allergy de-labeling by primary care physicians. | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 136 |
Characterization of Sulfonamide Allergy in the Veteran Population | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 137 |
SARS-CoV-2 and Perceived Physical, Mental and Social Health in Northern California | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 138 |
Error Analysis of Machine Learning Predictions on Asthma Hospital Encounters | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 139 |
Factors Associated with Allergen Immunotherapy-Related Systemic Reactions | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 140 |
Immunological mechanisms involved in dog dander allergoid response | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 141 |
Molecular allergy profile to house dust mites in Galicia (Spain) | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 142 |
Development of Basophil Activation Test (BAT)-based point-of-care diagnostic tool for allergies | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 143 |
Use of pollen mixes for skin prick testing is efficient but misses sensitization to some included pollens | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 144 |
Cellular Immune Parameters in Patients with Allerginic Rhinitis with Sensitization to House Dust Mite | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 145 |
EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 146 |
Absolute quantification of Bet v 1 in birch polymerized allergenic extracts via mass spectrometry-based targeted analysis | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 147 |
Post-Marketing Survey Evaluating the Safety and Efficacy of the SQ House Dust Mite (HDM) Sublingual Immunotherapy-Tablet in Japanese Patients with HDM-Induced Allergic Rhinitis (Stratified analysis by <18 years and > 18 years, 2016-2020) | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 148 |
Rapid and complete allergen delivery by a freeze-dried fast dissolving SLIT-tablet for ragweed allergy immunotherapy | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 149 |
Baseline Conjunctival Provocation Testing Score Predicts Grass-Specific Immunoglobulin Response | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 150 |
Geomapping Fungal Allergen Sensitization Across the United States | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 151 |
Sustained benefit of a 3-year cycle of subcutaneous house dust mite immunotherapy in local allergic rhinitis individuals | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 152 |
Post-marketing survey Evaluating the Safety and Efficacy of Japanese cedar pollen sublingual immunotherapy tablet (Stratified analysis by with or without asthma, 2018 to 2020) | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 153 |
Three Allergens Subcutaneous Inmunotherapy In Polen-Allergic Patients: Our Experience | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 154 |
Impact of Baseline Treatment, Duration of Disease, and Refractory Status on Outcomes in Mepolizumab-Treated Patients With EGPA | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 155 |
Tick salivary gland extract may act as an adjuvant to induce alpha-gal syndrome in alpha-gal deficient mice | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 156 | Eosinophilic Esophagitis Is Critically Mediated By IL-13 Signaling Via IL13Ra1 | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 157 |
Anakinra attenuates epithelial-derived pro-inflammatory cytokine release after rhinovirus infection | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 158 |
GLP-1R agonist treatment down-regulates cytokine-induced allergic inflammatory responses in human lung microvascular endothelial cells | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 159 |
A Versatile High-Dimensional Tool for Identifying T-Cell Immunophenotypes Linked to Different Types of Asthma | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 160 |
A Single-Dose Weight-Based Challenge Predicts the Minimally Effective Daily Dose of Prednisone in Hypereosinophilic Syndrome | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 161 |
Development of Milk Allergy Models in Mice Induced by Epicutaneous Exposure | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 162 |
A role for GLI transcription factors in the proliferation and survival of human mast cells | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 163 |
Lipopolysaccharide (LPS) pre-treatment skews the cytokine milieu early during the infection to prevent airway hyperresponsiveness | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 164 |
Sting regulates epithelial mesenchymal transition induced in chronic allergic lung inflammation | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 165 |
Prion-specific IgE activates human mast cells to release proteases | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
| 166 |
Effect of NLRP3 inhibition in allergic rhinitis mice model | Poster Session | 2/26/22 | 9:45 am - 10:45 am |
0201 Basic Aeroallergen Course
In-Person Course2/24/22, 8:30am - 5pm
8:30 am - 5:00 pm
| 228 |
Gastric Acid Suppression and Penicillin Allergy Label | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 229 |
Safety of Cefazolin for Perioperative Prophylaxis in Patients with Penicillin Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 230 |
Underutilization of Penicillin Allergy Evaluations during Pregnancy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 231 |
Mono and Biallergenic-Dendrimer Based Silica Particle for Specific IgE Determination to Betalactams | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 232 |
Educational Intervention to Improve Skin Test Utilization in Low-Risk Penicillin Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 233 |
THE ROLE OF CLAVULANIC ACID IN IMMEDIATE ALERGIC REACTIONS TO BETA-LACTAMS. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 234 |
Comparison of two strategies for increasing primary care referral for penicillin allergy testing | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 235 |
Current Knowledge and Management of Penicillin Allergy by Primary Care Physicians and Points for Improvement | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 236 |
Raising Awareness among Medical Residents to De-label Penicillin Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 237 |
CD203c showed greater diagnostic value than CD63 for evaluating immediate reactions to amoxicillin-clavulanic by basophil activation test. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 238 |
Direct Oral Challenge is a Safe and Effective Strategy to Delabel Low-Risk Penicillin Allergy in Immunocompromised Patients Admitted to the ICU | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 239 |
Dendritic Nanostructures for Effector Cell Activation to Study Allergic Reactions to Amoxicillin | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 240 |
Beta-lactam Allergy Assessment and Skin Testing (BLAAST) | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 241 |
Direct provocation in children with non-immediate reaction to beta-lactam | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 242 |
Detection Of Serum Specific IgE By Fluoro-Enzyme Immunoassay For The Diagnosis Of Immediate Allergic Reactions To Penicillins | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 243 |
Beta-lactam hypersensitivity in ambulatory and hospitalized patients are not similar and required different diagnostic approaches | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 244 |
Penicillin-Allergy No More: An interdisciplinary, pilot QI project in de-labeling ß-lactam allergies in a select group of surgical patients | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 245 |
Diagnostic Utility of Including Ampicillin in Performance of Penicillin Skin Testing | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 246 | Association of social vulnerability and current asthma prevalence in adults at the census tract level | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 247 |
Farm exposure and rates of early life respiratory illness and wheeze | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 248 | Nasopharyngeal airway dual-transcriptome of infants with severe bronchiolitis and risk of childhood asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 249 | Indoor Dust Bacterial and Fungal Microbiome in Homes of Asthmatic Children from 5 US Cities | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 250 |
Patterns of High-risk Systemic Corticosteroid Exposures, Short-acting Beta2-agonist Utilization, and Adverse Health Conditions in Children with Asthma in the United States | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 251 |
The Association between Public versus Private Insurance and Poor Asthma Control in the Pediatric Population Using the 2013 and 2018 National Health Interview Survey | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 252 |
Monitoring of Nighttime Respiratory Patterns to Alert for Changes in Chronic Asthma Management | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 253 |
Parental Acculturation and Child Asthma Control in Latino/a/x-origin Families | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 254 |
Food Deserts and Lung Function During Early Life | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 255 |
The Effectiveness of a Clinically Driven Home-Based Intervention in Houston-Area African American Adults with Poorly Controlled Asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 256 | Food and Housing Insecurity and its Effect on Asthma Control During the Covid-19 Pandemic | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 257 |
Neonatal rhinorrhea predicts childhood asthma symptoms and increased heart rate variability. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 258 |
Lengthy Process Of Biologic Approval And Administration Delays Treatment Of Patients With Moderate-To-Severe Asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 259 |
Lower Household Income is Associated with Higher Airway Inflammation and Furry Animal Allergen Sensitization in Urban Children with Exacerbation-Prone Asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 260 |
Internalizing behavior problems in early life are associated with the risk of childhood asthma: The COCOA study | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 261 |
Impact of Clinical and Biomarker Covariates on the Ability of the Asthma Impairment and Risk Questionnaire (AIRQ®) to Predict Future Exacerbations | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 262 |
Real-world Biologic Administration and Adherence Among US Subspecialist-treated Adults with Severe Asthma Differs by Biologic: Results from the CHRONICLE Study | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 263 |
Trends in Hospitalization for Serious Infections in children with Asthma in the US (2001-2014) | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 264 |
Maternal hypertensive disorders of pregnancy and the risk of childhood asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 265 |
Patient Use Of Non-Standard Terms For Asthma Inhalers Is Associated With Worse Asthma Morbidity Outcomes | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 266 |
The Racial and Ethnic Makeup of the Asthma Clinical Trials informing the 2020 NHLBI asthma guidelines update | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 267 | Asthma In New York City: Examining Trends In Hospitalizations Among Children | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 268 |
The Inverse Relationship of Asthma and Metabolic Markers in Children with Severe Obesity | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 269 |
Suboptimal Adherence to Controller Medication is Widespread Among Asthma Patients Escalated to Biologics: an Analysis of US Claims Data | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 270 | PREVALENCE AND RISK FACTORS FOR ASTHMA IN SCHOOLS. IS THERE A DIFFERENCE BETWEEN RURAL AND URBAN AREAS? | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 271 |
Pulmonary function characteristics in children with symptoms of asthma and its implications for asthma diagnosis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 272 |
Pathways of Escalation to Asthma Biologics in Real-world Clinical Practice: an Analysis of US Claims Data | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 273 |
Incidence of Conditions Commonly Associated With Corticosteroid Therapy in Asthmatics Versus Non Asthmatics Among a Large Insured Population | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 274 |
Moderate-to-Severe Asthma: Clinical Features and Endotypes of Peruvian Pediatric Patients | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 275 |
Patient Characteristics and Treatment Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 276 |
A Retrospective Chart Review Evaluating Adherence to Biologic Therapy in Patients with Severe Asthma Seen in a Pediatric Tertiary Care Center | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 277 |
Chronic Cough: Referral Sources, Etiology, Prevalence, Symptoms and Treatments In Adults A Survey of Allergy Specialists | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 278 |
Microbiome of the Bronchi in Moderately Severe Asthmatics with Type 2 Diabetes Mellitus Influences Airflow Obstruction | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 279 | Exacerbation-related alterations in upper airway microbial composition and biodiversity in asthmatic children | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 280 | Simultaneous measurement of surface proteins and single cell mRNA expression profiling of circulating immune cells in alpha-gal syndrome | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 281 |
Status Of Vitamin D In Children With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 282 |
Alpha gal allergy and its connection to cardiovascular bioprostheses | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 283 |
Comparative Review of Subcutaneous Immunotherapy and Nocturnal Vestibular Immunotherapy in Allergic Rhinitis Patients | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 284 |
Blood Monocytes are Associated with Body Mass Index and Hypertension in Inner-City Diabetic Adults | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 285 |
IL-10+ regulatory B cells are dysregulated in patients with seasonal and perennial allergy. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 286 |
Non-Atopic Infants Have Distinct Plasma Cytokine Profiles Compared to Atopic Infants | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 287 |
Assisting Front Liners: The Benefits Of Allergy Consultation On The Challenges To Covid Vaccination | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 288 |
Multidisciplinary Institutional Practice Plan to Safely Administer COVID-19 Vaccination to Health Center Employees | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 289 |
Vaccination against COVID-19 Leads to Enhanced Immunity Despite Infection History | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 290 |
Evaluation of Immunogenicity of an Inactivated SARS-CoV-2 Vaccine Prototype in vitro | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 291 |
Antibody Response to SARS CoV-2 Immunization in Patients with Immunodeficiency | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 292 |
Predictors Of Seroconversion Following COVID-19 Vaccination | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 293 |
Outcomes from New Consultations to Allergy Clinic for COVID-19 Vaccine Concerns | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 294 |
Pneumococcal Vaccinations In Young Adults With HIV | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 295 |
Influenza vaccination patterns in an Allergy specialty clinic during COVID-19 | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 296 |
Fractional Administration of COVID19 Vaccine Induces an Antibody Response | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 297 |
SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 298 |
Lactobacillus acidophilus causes enhancement of the intestinal tight junction barrier by a toll-like receptor-2-dependent increase in occludin | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 299 |
Are gelatin-containing vaccines safe to give in alpha-gal sensitized patients? | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 300 | Asthma-Related Emergency Department Visits in Texas: Associations with Allergenic Pollen and Viruses | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 301 |
Regular Use of Nasally Applied Methyl-cellulose Powder During the Pollen Season Protects Against Sars-Covid-2 Infections | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 302 |
Charlson Comorbidity Index and National Early Warning Score 2: Predictors of Mortality in COVID-19 Hospitalizations | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 303 |
Spike Antibody Assays Can Screen For Viral Neutralizing Activity Toward SARS-CoV-2 | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 304 |
Predictive factor analysis for Macrolide Refractory Mycoplasma pneumonia | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 305 | Exhaled nitric oxide is decreased in Sars-Cov-2 infection | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 306 |
Allergic Reactions During Travel Among Individuals With IgE-mediated Food Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 307 |
Allergy Outcomes at 12 months in children born during COVID-19 lockdown : the CORAL study | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 308 |
Understanding Sesame Allergy in the Pediatric Population | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 309 |
Factors associated with continued peanut, treenut and sesame ingestion post successful oral food challenge | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 310 |
Fad Foods & FPIES – Is Avocado Really a Low Risk FPIES Food? | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 311 |
Don’t Hold the Tahini: A Retrospective Chart Review of Sesame Oral Food Challenges in a Pediatric Food Allergy Clinic | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 312 |
Food Sensitization and DNA methylation at age one in the CHILD Cohort | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 313 |
Defining Sesame Sensitization Patterns in Infants and Toddlers | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 314 |
Food Allergic Reactions In U.S. Schools | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 315 |
Impact of the LEAP Study on Age at Introduction of Peanut in a Suburban U.S. Cohort | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 316 |
Multifaceted approach to limit ordering of IgE food testing | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 317 | Major Peanut Allergens Ara h 1, Ara h 2 and Ara h 8 Are Degraded and Fragmented Following High-Pressure and Temperature Autoclaving | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 318 |
Disrupted Foodways: Food Allergies and Food Insecurity | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 319 |
Untargeted Metabolomic Profiling Identifies Shared and Age-specific Alterations in Children with Food Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 320 |
Prevalence and characteristics of accidental ingestions in a prospective cohort | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 321 | Immunological markers to determine the optimal timing of oral food challenge for introduction of dietary wheat in children with IgE mediated wheat allergy. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 322 |
Moving Away from Routine Emergency Department Evaluation After Treatment of Anaphylaxis – A Retrospective Review of Epinephrine Usage Among High-Risk Peanut-Allergic Children | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 323 |
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 324 |
Initial Findings in Efficacy Evaluation of a Novel Clinical Support Tool: The Food Allergy Passport | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 325 |
Timing of Allergy Skin Testing Following Food-Induced Anaphylaxis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 326 |
Feasibility of Virtual Reality Technology to Improve Experience During Pediatric Oral Food Challenge | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 327 |
The impact of food allergy on mental health in school-age children | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 328 |
Timing Of Testing For IgE-mediated Food Allergy After Systemic Reaction | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 329 |
Characteristics of Patients with Food Allergy & Food Insecurity on a Prescription Supplemental Nutrition Program | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 330 |
Is Skin Prick Test (SPT) Better Than Specific IgE (sIgE) For Predicting Oral Food Challenge (OFC) Outcomes For Pediatric Patients With Pecan And Walnut Food Allergy? | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 331 |
Identifying Deficiencies in Food Allergy Awareness and Accommodation on College Campuses | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 332 |
Home Introduction Of Baked Egg After Oral Food Challenge | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 333 |
Oral Food Challenge Outcomes at McMaster University Over Two-years | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 334 |
Likelihood Ratios for Reactions to Egg based on Specific IgE and Oral Challenges | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 335 |
Specific IgE to Total IgE Ratio Does Not Improve Peanut Diagnostic Accuracy in Adults | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 336 |
Diagnostic Algorithms for Cashew Allergy in Children Reduce Oral Food Challenges and Overall Cost. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 337 |
Fish and shellfish allergy: Are they different in different countries? | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 338 |
Time to Resolution of Milk Allergy Utilizing Baked-Milk Diet | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 339 |
Significant Reduction of Specific Allergen Levels in Baked Egg Foods | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 340 |
Analysis of Oral Food Challenge Outcomes to Sesame | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 341 |
Children Who Are Sensitized to Almond Without a History of Prior Exposure Have a High Likelihood of Passing Almond Challenge | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 342 |
Analysis of Clinical Food Allergen Thresholds by Comparing Threshold Dose Distributions | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 343 |
Use of Basophil Activation Test in Peach Allergy Diagnosis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 344 |
Clinical and Sensitization Profile in Peach Allergy due to LTP Sensitization. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 345 |
Lupine allergy cross-reactivity with Fabaceae family | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 346 | The Utility of Specific IgE to Total IgE Ratios in Predicting Outcomes of Baked Egg Oral Challenge | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 347 |
Oral Food Challenge In Children Presenting Contact Urticaria To Cow Milk | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 348 | Toll-like receptor ligand-peptide conjugates in the immunomodulatory response of food allergy. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 349 |
Basophil Activation Testing in Baked Egg and Nut Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 350 |
Benefits of mobile application in food allergy patients and caregivers | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 351 |
Disparities in the conduct of oral food challenges between Black and White children in the FORWARD cohort | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 352 |
Reactions from Single and Multiple food allergies: Participant Experiences from the FARE (Food Allergy Research) patient registry | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 353 |
Multi-Disciplinary Development of a Novel Caregiver and Patient Clinical Support Tool: The Food Allergy Workbook | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 354 |
Household-Wide Food Allergen Exclusion Practices Among Families with Food Allergies | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 355 |
Eosinopenia And COVID-19 Severity: Is There A Relationship? | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 356 |
Children With Shellfish Allergy Have A Higher Risk Of Cockroach Sensitization | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 357 |
Food Allergies and Health Disparities: How Socioeconomic Differences Correlate with Delayed Introduction of Food Allergens | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 358 |
Content Validation of the Psychosocial Evaluation of Allergy on Caregivers and Households (PEACH) Tool | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 359 |
Psychoemotional Experiences among Adults with Food Allergy: An Exploration of Novel Coping Strategies | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 360 |
Trends in the Proportion of Women Speakers at North American Allergy and Immunology Conferences over a 12-year Period | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 361 |
Variability in Perceptions of Food Allergy Severity, Worry, and Risk of Allergen Exposure among Youth with Food Allergy and their Parents | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 362 |
Global Availability and Uptake of Psychological Services for Caregivers of Children with Food Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 363 |
Gendered Disparities Regarding Use of Allergen Immunotherapy in Pediatric and Adult Populations | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 364 |
Racial and Ethnic Disparities with Allergen Immunotherapy in Patients with Allergic Rhinitis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 365 |
Allergy In Early Childhood Is A Risk Factor For The Development Of Attention Deficit Hyperactivity Disorder (ADHD) | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 366 |
Disease Burden Among Patients With Multiple Overlapping Eosinophilic Diseases In The Real World Investigation Of Eosinophilic-Associated Disease Overlap (REVEAL) Study | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 367 |
Using the Munich Oktoberfest to assess the prevalence and treatment of allergies | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 368 |
Latino CRS Patients Have Comparable Outcomes to White Patients Before and After Treatment of CRS | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 369 |
Allergy and Immunology Advanced Practice Provider Continuing Education Curriculum | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 370 |
Executive Functioning Skills and Food Allergy-Related Psychosocial Functioning among Parents of Young Children with Food Allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 371 |
Validation of the parent-proxy reported Food Allergy-related Quality of Life Questionnaire (FAQLQ-PF-10) short form in a large, multisite longitudinal cohort of food allergic child-parent dyads | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 372 |
Early Peanut Introduction Guidelines and Parental Anxiety | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 373 | A Multi-Center Evaluation of Anxiety, Depression, and Resilience in Food Allergic Adolescents and Primary Caregivers during the COVID-19 Pandemic | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 374 | Vitamin D, Skin Filaggrin, Allergic Sensitization, and Race: a Complex Interplay. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 375 |
Transition to Subcutaneous Immune Globulin 16.5% Improves Patient-Reported Quality of Life | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 376 |
Improvement of Quality of Life and Positive Feedback in Long-Term Follow-Up Study in Food Allergic Participants with Oral Immunotherapy Treatment | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 377 |
Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 378 | CDHR3 rs6967330 risk allele influences CRS disease severity | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 379 |
The Challenge Of When To Challenge: An Investigation Into Aspirin-Exacerbated Respiratory Disease (AERD) Screening Methodology | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 380 |
A Single-Center, Randomized, 3-Way, Crossover Study to Evaluate the Effect of an Exhalation Delivery System on Nasal Nitric Oxide Concentrations in Patients with Chronic Rhinosinusitis Compared with Healthy Participants | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 381 | Clinical Characteristics may help predict refractoriness to endoscopic sinus surgery in patients with Chronic Rhinosinusitis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 382 |
The relationship between sleep disturbances and allergic rhinitis in Korean children and adolescents. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 383 | The correlation between sleep quality and the severity of allergic rhinitis in Korea | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 384 |
Potential of BAFF in Nasal Secretions as a Marker of Allergic Rhinitis Severity in Children | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 385 |
Association Between IgE Levels and COVID-19 Mortality | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 386 | Serum levels of Galectin-10 increase in active eosinophilic granulomatosis with polyangiitis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 387 | CD4+ and CD8+CD60+ T cells in PBMC of IgE+ allergic adults express IL-4 or IFN alpha but not IFN gamma, and some express receptors for complement split products (CSP) C3a and C5a. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 388 |
Assessment of the Correlation Between Energy Expenditure and Muscular Mass with Production of Immunoregulatory Cytokines in Ice Hockey Players | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 389 |
Novel Methods for Studying Platelet-Mediated Inflammation in Asthma | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 390 |
The Trend Of IgE Levels In Patients With IgE Deficiency | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 391 | An algorithmic approach employing tryptase genotyping clarifies clinical conditions that are associated with elevated basal tryptase | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 392 |
Human IgE monoclonal antibodies in the design of a novel in vitro model of the effector phase of peanut allergy | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 393 |
Contributions of Adult Body Mass Index (BMI) and total serum IgE to CD33+ monocyte iNOS responses in vitro. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 394 |
Culturing of Bacterial Isolates from Skin of Pediatric Atopic Dermatitis Subjects | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 395 | Survey of the Oral and Intestinal Microbiome in Patients with Systemic Mastocytosis | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 396 | Distributions of T cell subsets expressing receptors for complement split products (CSP) C3a or C5a in blood of serum IgE+ aeroallergen allergic adults. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 397 | Effect of autologous plasma on CD33+ monocyte iNOS responses in vitro. | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 398 |
Assessment of Diagnostic Equivalence of Biological Secretions in Men with Chronic Prostatitis /Chronic Pelvic Pain | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 399 |
Seasonal and Lab Variation of Serum Tryptase | Poster Session | 2/27/22 | 9:45 am - 10:45 am |
| 490 |
Sustained Reductions in Hereditary Angioedema (HAE) Attack Rates Observed over 96 Weeks of Oral Berotralstat Treatment Regardless of Initial Response | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 491 |
Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 492 |
Sustained Improvement Observed in Patient-Reported Quality of Life (QoL) with 96 Weeks of Oral Berotralstat Treatment | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 493 |
Pharmacodynamics and Pharmacokinetics of PKK-LRx in Patients with Hereditary Angioedema | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 494 |
An Open-label Trial With Plasma Prekallikrein Oligonucleotide Antisense Therapy To Control Angioedema Attacks In Hereditary Angioedema Patients With Normal C1-inhibitor | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 495 |
Long-term effectiveness and safety of lanadelumab in the US and Canada: Findings from the EMPOWER Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 496 |
Impact of lanadelumab on patient-reported outcomes in hereditary angioedema in the US and Canada: Interim findings from the EMPOWER Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 497 | Patient-reported outcomes (PROs) in patients with hereditary angioedema receiving lanadelumab: interim findings from the ENABLE study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 498 |
Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 499 | A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Omalizumab for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 500 |
Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated With Early Symptom Relief in Patients With Hereditary Angioedema | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 501 |
QLS-215 is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 502 |
Treatment patterns among patients with HAE-C1-INH: Interim analysis findings from US and Canada participants in the EMPOWER study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 503 |
Characterization of Treatment Responses in Acquired Angioedema | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 504 |
A Multicentre UK-Based Audit on Acquired C1 Inhibitor Deficiency 2021 | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 505 |
Hereditary Angioedema-Online CME Improves Knowledge and Confidence among Allergists & Clinical Immunologist’s and Pediatrician’s related to the Management of Attacks | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 506 |
The Impact on Quality of Life Following Treatment with Plasma Prekallikrein Targeted Oligonucleotide Antisense Therapy in Hereditary Angioedema Patients | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 507 |
CRISPR/Cas9-mediated KLKB1 Gene Editing and Serum Kallikrein Reduction by NTLA-2002 Remains Durable in Humanized Mice Following Liver Regeneration after Partial Hepatectomy | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 508 |
Biomarkers Commonly Associated with Urticaria Severity Do Not Correlate With Angioedema Activity Scores | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 509 |
Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary Angioedema | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 510 |
HAE with normal C1-INH: Treatment and attack frequency based on data from the Canadian 2020 national survey | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 511 |
Anaphylaxis in Hypersensitivity reactions to NSAIDs | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 512 |
NSAID-Exacerbated Respiratory Disease in Pediatric Severe Asthmatic Population | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 513 |
Prevalence Of Acetaminophen Intolerance Among Patients With Aspirin Exacerbated Respiratory Disease At A Tertiary Care Institution | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 514 |
A One Day Outpatient Aspirin Desensitization Protocol With Home Dose Escalation For Patients With Aspirin Exacerbated Respiratory Disease (AERD). | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 515 |
Machine learning approach for culprit drug identification based on drug-specific interferon-gamma releasing cells and clinical parameters in non-immediate drug hypersensitivity | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 516 |
Do Oral Challenges Alter Prescribing Practices? A MarketScan Study Evaluating Use of First-Line Antibiotics for Sinus Infections | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 517 |
A Retrospective Review of Immediate Hypersensitivity Skin Testing and Graded Challenge to TMP-SMX for IgE-Mediated Sulfonamide Antibiotic Allergy | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 518 |
Evaluation Of The Outcomes Of Oral Challenges To Azithromycin, Cephalexin And Trimethoprim-Sulfamethoxazole In Pediatrics | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 519 |
Direct Rechallenges, Slowed Infusions, and Titrated Infusions following Platinum Hypersensitivity Reactions: Review of 5-Year Experience | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 520 |
Checkpoint inhibition induced pruritus during cancer therapy is associated with skin IL-31 and CCL22 expression | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 521 |
Allergen sensitization and the development of anaphylaxis to paclitaxel in cancer patients. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 522 | Efficacy of add-on therapy with intravenous immunoglobulin in steroid hypo-responsiveness DRESS syndrome | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 523 | COVID-19 mRNA Vaccination Appears Safe in Pediatric Patients With A Hypersensitivity Reaction To PEGylated Escherichia Coli L-Asparaginase | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 524 |
Urticarial and Eczematous Eruptions Following mRNA COVID-19 Vaccination in Patients With and Without Chronic Urticaria and Atopic Dermatitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 525 |
Patients with Pseudoallergic Reactions Following COVID-19 Vaccination are Able to Tolerate Subsequent Dosing | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 526 | Evaluating Iodixanol as a safe alternative in iodinated contrast hypersensitivity reactions | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 527 |
Comorbidities, Triggers, Management, and Rate of Resolution of Cholinergic Urticaria in 18 Pediatric Patients | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 528 |
Dermatographia with idiopathic postprandial diarrhea responsive to antihistamines: a case series | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 529 | IL-33 Enhances Histaminergic Itch | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 530 | Online Education Yields Significant Gains in Physicians’ Knowledge of Diagnosis and Management of Chronic Spontaneous Urticaria | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 531 |
Bridging knowledge gaps in pediatric urticaria through a video-based educational tool. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 532 | Effectiveness of Laboratory Testing in the Management of Chronic Urticaria/Angioedema | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 533 |
Serum free IgE in patients with chronic spontaneous urticaria (CSU) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 534 |
The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria (Cindu) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 535 |
Chronic Spontaneous Urticaria patients under Treatment with Omalizumab: Our Experience | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 536 |
Remibrutinib Treatment Improves Quality of Life in Patients with Chronic Spontaneous Urticaria | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 537 |
Ligelizumab for adolescent patients with CSU: first results from a dedicated Phase 2b study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 538 |
Ligelizumab Achieves Freedom from Signs and Symptoms of Chronic Spontaneous Urticaria Regardless of the CU Index (Basophil Histamine Release Assay) Status at Baseline | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 539 |
Ligelizumab Improves Dermatology Quality Of Life In Patients With Chronic Spontaneous Urticaria Regardless of Angioedema Status At Baseline | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 540 |
Efficacy Of Hydroxychloroquine in Refractory Chronic Idiopathic Urticaria (RCIU) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 541 | COVID-19 Vaccine Induced Flares of Chronic Spontaneous Urticaria: A Case Series | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 542 |
A Retrospective Study Evaluating Atopic Diseases in Patients with Allergic Contact Dermatitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 543 | Sensitization to Malassezia Sympodialis is Associated with Low Efficacy of Local Anti-inflammatory Therapy in Patients with Contact Dermatitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 544 |
Single-cell multi-omic approaches define common molecular and cellular signals of dominant antigen-driven cells at the site of drug-induced Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) tissue damage. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 545 | Cytokine Production in Psoriasis Patients with Comorbidities Correlates with Efficacy of Biologic Treatment | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 546 |
SDRIFE-like reaction with systemic affectation after SARS-COV-2 infection | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 547 | IL-17 Synthesis in Patients with Psoriasis Varies with Obesity and May be Regulated by Histamine Receptors | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 549 |
Novel Use Of Dupilumab In A Patient With Post-Acute Sequelae of SARS-CoV-2 Infection With Severe Persistent Asthma | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 550 | COVID-19 Concerns, Resilient Coping, and Socioeconomic Burden among Asthmatic Adults | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 551 |
Factors Leading to Reduced Unscheduled Pediatric Asthma Visits During COVID-19 | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 552 |
Covid-19 in outpatient and inpatient Asthmatics in Lebanon: Real-life experience | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 553 |
Difficult to Control Asthma During COVID-19 Lockdown | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 554 |
Changes in remote care adoption for asthma during the COVID-19 pandemic | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 555 |
Feasibility of capturing self-reported asthma exacerbations with a digital self-management platform | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 556 |
Mobile spirometry and digital health applications for remote monitoring of asthma in adolescents | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 557 |
Factors Affecting Adaptation of the AAAAI Picture-based Asthma Action Plan: a Survey-Based Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 558 |
Utility of Patient-Generated Health Data and Artificial Intelligence in the Prediction of Asthma Exacerbations | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 559 |
Feasibility of Telemedicine Home Assessments for Identification of Asthma Triggers in a Rural State | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 560 |
An Electronic App To Improve Satisfaction With Shared Decision-Making During Asthma Visits | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 561 | The ASTHMAXcel PRO Mobile Application’s Field Testing Results: Exit Interviews | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 562 |
Assessing the impact of technology-based interventions on patient outcomes for asthma in the emergency room: A scoping review | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 563 |
Type 2 inflammation changes airway nociceptors' transcriptome | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 564 | Clinical features of asthma with bronchiectasis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 565 |
Low Bronchoalveolar Lavage Absolute Granulocytes Differentiate A Novel Phenotype of Children with Severe Asthma: Decreased Allergen Sensitization and Normal Lung Function | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 566 | Characterization Of Alcohol Induced Respiratory Symptoms In Aspirin Exacerbated Respiratory Disease (AERD): The Happy Hour Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 567 |
Eosinophilic Granulomatosis with Polyangiitis Presenting as Aspirin Exacerbated Respiratory Disease; Report of 3 Cases | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 568 |
Distribution Patterns of Mite Allergens Among Children With Moderate-to-Severe T2 Asthma Endotype | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 569 |
Underuse of Biomarkers May Contribute to an Inability to Phenotype Severe Uncontrolled Asthma Patients and Diminish Oral Corticosteroid Burden. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 570 |
The Impact Of Baseline Exhaled Nitric Oxide Levels And Blood Eosinophil Count On Clinical Outcomes In REALITI-A | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 571 |
Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 572 |
Eosinophilia is Associated with Improved COVID-19 Outcomes in Patients Treated with Inhaled Corticosteroids | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 573 | Changes in oscillometry parameters in reversibility testing as predictors for cough variant asthma | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 574 |
Influence of Baseline Total IgE and History of Previous Omalizumab Use on the Impact of Mepolizumab in Reducing Rate of Severe Asthma Exacerbations: Results From the Real-World REALITI-A Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 575 |
Immune Profiles in Inner-city Asthmatic Children Receiving Frequent Systemic Steroids | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 576 | Bronchodilator response assessed by oscillometry identifies uncontrolled asthma with more sensitivity than spirometry | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 577 | Unique Nasal Epithelial Transcriptome Changes Discovered in AERD | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 578 |
Treatment by Biomarker-Informed Endotype Versus Guideline Care in Children with Difficult to Treat Asthma | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 579 |
Lack of Reliability of a Single Peripheral Blood Eosinophil Count as Biomarker for High Th2 Asthma | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 580 |
Evaluation of AsThma Endotypes (ELATE) Study: Rationale and Design | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 581 |
Combining Biologic Therapies Involving Anti-IgE, Anti-IL5, Anti-IL5R and Anti IL-4/IL-13: Experience from a Large Academic Health System | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 582 |
Vaping Prevalence Among Clinical Immunology Patients Receiving Therapy With Biologics | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 583 | Development of a multifunctional third generation anti-IgE therapeutic candidate antibody | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 584 |
A Micro-Learning Approach Improves Knowledge among Allergists and Otolaryngologists related to Chronic Rhinosinusitis with Nasal Polyps | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 585 |
Monoclonal antibody infusion for COVID-19 infection: results from a tertiary referral center | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 586 |
Pharmacodynamics of CT-P39, a Proposed Biosimilar of Omalizumab, Comparing with EU-Xolair and US-Xolair; Result of a Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study in Healthy Subjects. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 587 | Online Education Yields Significant Gains in Physicians’ Knowledge of Eosinophil-Associated Disorders | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 588 |
Tocilizumab: History and Future Perspectives in the Era of COVID-19 | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 589 | Characterizing Sarcoidosis at a Quaternary Referral Center: Clinical, Diagnostics, and Genetic Features of Sarcoid-like Illness Presentations | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 590 |
Antibody Deficiency in ANCA Associated Vasculitis (AAV) Patients Treated with Rituximab | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 591 |
Germline RUNX1 Deficiency Predisposes to Allergic and Autoimmune Disease and is Associated with Increased Th2 and Th17 Memory CD4+ T Cells | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 592 |
Interaction between peripheral T helper cells and CD11c+CD21- B cells underlies the pathogenesis of IgG4-related disease | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 593 | CD8αα Expression on NK cells is Associated with Different K562 and MOLT4 Killing Capabilities of PBMC | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 594 |
B-cell driven autoimmunity in patients with genetically defined autoinflammatory disorders | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 595 | A comparison of risk factors of allergic diseases between island and inland town in Incheon. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 596 |
Obstacles In Deciphering Species: Processing Airborne Fungi With A Metagenomics Workflow | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 597 |
Amplification of Local Mulberry Pollen by Import to Southern Ontario | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 598 |
How well do volunteer-contributed observations of flowering characterize the springtime airborne pollen season? | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 599 |
Clinical Trial Experience With a New Pollen Sampling Network In The US | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 600 |
“Atmospheric Pollen Count And Its Airborne Calendar In Northeastern Mexico" | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 601 |
Iowa Pollen Counts During a Derecho Wind Storm and Autumn Weed Pollen Seasons | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
601 2022 ABAI Continuous Assessment Program Literature Review Course
In-Person Course2/24/22, 2:30pm - 4:30pm
2:30 pm - 4:30 pm
| 601 | 2022 ABAI Continuous Assessment Program Literature Review Course | In-Person Course - OD | | |
| 602 |
Airborne Pollen Reached Severe Levels During the Spring Season in an Underserved Community with High Asthma rates in Jacksonville Florida. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 603 | Annual Comparison of Poaceae Pollination In Lima (Perú) And Bahia Blanca (Argentina). | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 604 |
Amaranthaceae is an Underestimated Summer Allergen with Sensitization Often Underappreciated | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 605 | Asteraceae Pollen Rainfall Comparison in Four South American Cities | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 606 |
Alpha-Gal Allergy and Mast Cell Hyperactivity Overlap | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 607 | Co-localization of Immunoglobulin G4 (IgG4) and milk proteins is associated with Eosinophilic Esophagitis (EoE) disease activity. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 608 |
Evaluation of an Allergen Free Pig for AGS Patients | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 609 |
Effect of Dupilumab on Eosinophilic Esophagitis when used for other approved indications | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 610 |
IgE Independent Induction of EoE by Airborne Antigens via Up-regulation of Th2 Responses | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 611 |
IgG4 to cow’s milk proteins in an adult cohort: high-level specific IgG4 is associated with IgE and cow’s milk consumption | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 612 |
GATA-3 and T-bet as diagnostic markers of non-esophageal eosinophilic gastrointestinal disease | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 613 |
Thymic stromal lymphopoietin isoform expression in eosinophilic esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 614 | LIGHT Deficiency Protects Against Esophageal Remodeling In A Murine Model Of Chronic Eosinophilic Esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 615 |
Peripheral Blood Cell Counts Predict Distinct Endoscopic Phenotypes In Eosinophilic Esophagitis. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 616 | Esophageal Fibroblasts are the Players in the Interferon Response in Eosinophilic Esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 617 |
Assessment of mouse esophageal contractility | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 618 | Longitudinal Association of Parent and Child Patient Reported Outcomes in Eosinophilic Esophagitis in a Multicenter Cohort | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 619 | Body mass index in relation to presenting symptoms and age upon diagnosis of Eosinophilic Esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 620 |
Association Between Tick Bites and Alpha-gal Syndrome: A Case-Control Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 621 |
Comparison of Food Allergy in Participants with and without Comorbid Eosinophilic Esophagitis from the Food Allergy Research & Education (FARE) Patient Registry | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 622 |
The Association of Food Protein-Induced Enterocolitis Syndrome (FPIES) with Personal and Familial Co-Morbidities | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 623 |
Food Protein-Induced Enterocolitis Syndrome (FPIES): Natural History and Reintroduction in the Early Peanut Introduction Age | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 624 | Alpha-Gal sensitization, mammalian meat consumption and allergic symptoms in adults from central Virginia at-risk for cardiovascular disease | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 625 |
Prevalence of α-Gal IgE and Mammalian Meat Allergy in a COVID-19 Vaccine Employee Cohort | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 626 | Effect of proton Pump Inhibitor on Kidney function in a pediatric population with Eosinophilic Esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 627 |
Oral food challenge in adults with food protein-induced enterocolitis syndrome: a case series. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 628 |
Efficacy of Budesonide versus Fluticasone in Children with Eosinophilic Esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 629 |
Development of an Action Plan for Acute Food Protein–Induced Enterocolitis Syndrome in Japan | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 630 |
Alpha-Gal Allergy: Characteristics of a Midwest Cohort | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 631 | Evidence for a Causal Role for Milk Specific IgG4 in EoE | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 632 |
Food-specific IgG4 is elevated throughout the upper gastrointestinal tract in eosinophilic esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 633 |
Dupilumab Reduces Biomarkers of Type 2 Inflammation in Adult and Adolescent Patients With Eosinophilic Esophagitis: Results From Parts A and C of a Three-Part, Phase 3 LIBERTY EoE TREET Study | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 634 |
The Prevalence of Dysphagia and Food Impactions is High in Atopic Patients Without a Known History of Eosinophilic Esophagitis (EoE) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 635 |
Peptide Biased Antagonist Targeting CCR3 Blocks Esophageal Eosinophil Recruitment in the L2-IL5OXA Transgenic Mouse Model of Eosinophilic Esophagitis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 636 |
Understanding the Perspectives of Asthma Patients and Caregivers to Improve Shared Decision-Making and Satisfaction With Care | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 637 |
Anxiety among Early Adolescents with Food Allergy | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 638 |
Innovative Educational-Empowerment-Empathy Networks for/by Allergic-Immunodeficient Children/Teens/Adults – Inclusive Model towards Health Literacy Reproducible across Chronic Diseases | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 639 |
Career Readiness Identified as Unmet Need in Fellowship Training | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 640 |
A Safe Asthma Camp for Children During COVID | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 641 |
Evaluation of Mobile Apps for Food Allergy | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 642 |
Adherence with Passive Versus Active Monitoring of Respiratory Biomarkers | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 643 |
Improve Eczema/Asthma Research Study Enrollment and Retention Using Engaging, Participant Co-designed Graphic-Style Stories | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 644 |
Increasing Accessibility of the Food Allergy Action Plan via the Phone Friendly Food Allergy Action Plan | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 645 |
Caregiver treatment preferences for children and adolescents with asthma: a discrete choice experiment | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 646 |
PCORI Engagement: Black People Like Me | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 647 |
Not One More Life Trusted Messenger Pilot Program | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 648 |
Allergists are interested but lack training in approaches for how to prepare schools for allergy emergencies. | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 649-B |
Pediatric Clinician Attitudes and Knowledge Regarding Food Introduction | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 649 |
Survey of Influenza/Covid-19 Vaccination of High risk Brooklyn Residents | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 650 | Severe Ocular Allergy In Brazilian Children And Adolescents | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 651 |
A Phase III Double-Masked, Crossover, Vehicle-Controlled Clinical Trial Conducted in an Environmental Exposure Chamber (EEC) to Study Reproxalap, a Novel, Non-Antihistaminic, Non-Steroidal, Reactive Aldehyde Species Inhibitor for the Treatment for Allergic Conjunctivitis (AC) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 652 | Ocular Allergic Surface Disease Symptoms Associated with Atopic Keratoconjunctivitis (AKC) Alleviated With Dupilumab | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 653 |
Dry eye syndrome in patients with allergic eye disease | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 654 |
Allergenicity Analysis of Pru p 9 IgE-epitope: The First Peach Aeroallergen | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 655 |
Proteomic evaluation of Alternaria alternata spores, hyphae, and commercial allergen extracts | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 656 |
Evolution and functional significance of cat allergen, Fel d 1 | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 657 |
High quality purification of German cockroach vitellin/vitellogenin from whole body acetone defatted powder | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 658 |
Cytokine Analysis of Serum Before and After Nasal Allergen Challenge with Ragweed Extract | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 659 |
Unique Epitope for a Natural Human IgE Monoclonal Antibody on Der p 2 | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 660 |
Alpha-gal as the newest member of the glycan epitopes recognized in allergen nomenclature for cross-reactive carbohydrates | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 661 |
Comorbidity and Disability in Medicare Beneficiaries Newly Diagnosed with Non-Advanced Systemic Mastocytosis (Non-AdvSM) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 662 |
Allergic Diseases and Anaphylaxis in Mastocytosis | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 663 |
Clinical Characteristics, Management and Triggers of Mastocytosis in a Cohort of 39 Patients | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 664 |
Utility of a Validated Disease-Specific Measure to Assess Symptomology in Patients with Indolent Systemic Mastocytosis (ISM) | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
| 665 |
A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome | Poster Session | 2/28/22 | 9:45 am - 10:45 am |
1011 2022 FIT Symposium
In-Person Course2/25/22, 7am - 1:30pm
7:00 am - 1:30 pm
1012 2022 Chrysalis Project Program (Invitation Only)
In-Person Course2/25/22, 7:30am - 1:45pm
7:30 am - 1:45 pm
| 1101 | Allied Health: Using a Team Approach to Allergy/Immunology Care: A Collaborative Model Using Medical Doctors, Advanced Practice Nurses, Registered Nurses, Physician Assistants and Medical Assistants | In-Person Workshop | 2/25/22 | 8:00 am - 9:15 am |
| 1101 | Allied Health: Using a Team Approach to Allergy/Immunology Care: A Collaborative Model Using Medical Doctors, Advanced Practice Nurses, Registered Nurses, Physician Assistants and Medical Assistants | In-Person Workshop - OD | | |
| 1102 | Allied Health: Finding the Zebra: Understanding How to Diagnose an Immune Disorder | In-Person Workshop | 2/25/22 | 8:00 am - 9:15 am |
| 1102 | Allied Health: Finding the Zebra: Understanding How to Diagnose an Immune Disorder | In-Person Workshop - OD | | |
1110 Developing and Maintaining Excellence in Allergy/Immunology Fellowship
In-Person Course2/25/22, 7:30am - 12pm
7:30 am - 12:00 pm
1201 2022 Difficult Cases
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1201 | 2022 Difficult Cases | In-Person Course - OD | | |
1202 From Acute to Chronic, the Many Faces of Urticaria
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1202 | From Acute to Chronic, the Many Faces of Urticaria | In-Person Course - OD | | |
1203 Lessons Learned from National Institutes of Health (NIH) Severe Asthma Networks on Evaluating and Managing Difficult-to-Control Asthma
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1203 | Lessons Learned from National Institutes of Health (NIH) Severe Asthma Networks on Evaluating and Managing Difficult-to-Control Asthma | In-Person Course - OD | | |
1204 It All Matters: A Multi-Pronged Approach to Asthma Pathogenesis
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1204 | It All Matters: A Multi-Pronged Approach to Asthma Pathogenesis | In-Person Course - OD | | |
1205 Diagnostics in Allergy & Immunology: An Update
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1205 | Diagnostics in Allergy & Immunology: An Update | In-Person Course - OD | | |
1206 The Clinical Utility of Pollen and Mold Counts in the Allergy Office
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1206 | The Clinical Utility of Pollen and Mold Counts in the Allergy Office | In-Person Course - OD | | |
1207 Ethnic and Racial Differences in Food Allergy
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
1208 Expanding Your Practice: Clinical, Administrative and Reimbursement Strategies for Success
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1208 | Expanding Your Practice: Clinical, Administrative and Reimbursement Strategies for Success | In-Person Course - OD | | |
1209 Engaging Your Learners at the Annual Meeting with Innovative Approaches
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
1210 Introductory Rhinolaryngoscopy Course with Hands-On Learning
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1210 | Introductory Rhinolaryngoscopy Course with Hands-On Learning | In-Person Course - OD | | |
1211 Metabolic Regulation of Viral and Inflammatory Disease
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1211 | Metabolic Regulation of Viral and Inflammatory Disease | In-Person Course - OD | | |
1212 How to Survive as an Academic Translational Scientist Pursuing Asthma/Allergy/Immunology Research in the Current Funding Environment
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
1213 Allied Health: An Update on Allergic Conditions in 2021 for the Allied Health Provider
In-Person Course2/25/22, 9am - 12pm
9:00 am - 12:00 pm
| 1213 | Allied Health: An Update on Allergic Conditions in 2021 for the Allied Health Provider | In-Person Course - OD | | |
| 1250 | Allied Health: Difficult Cases: What to Do When Nothing Works | In-Person Workshop | 2/25/22 | 9:30 am - 10:45 am |
| 1250 | Allied Health: Difficult Cases: What to Do When Nothing Works | In-Person Workshop - OD | | |
| 1251 | Allied Health: The Impact of the Vaping Epidemic on Teens and Young Adults with Asthma | In-Person Workshop | 2/25/22 | 9:30 am - 10:45 am |
| 1251 | Allied Health: The Impact of the Vaping Epidemic on Teens and Young Adults with Asthma | In-Person Workshop - OD | | |
| 1501 | Practical Approach to Aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Challenges and Desensitizations for Patients with Aspirin-Exacerbated Respiratory Disease (AERD) and Other NSAID Allergies | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1502 | Update on the Guidelines for Work-Up and Management of Patients with 22q11.2 Syndrome | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1503 | The Best Possible Care for Children with Severe Asthma | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1504 | Older Adults with Severe Asthma: Updates on Optimal Management | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1505 | The Role of the Practicing Allergist in the Management of Eosinophilic Esophagitis | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1506 | Food Allergen Advisory Labels: Avoid or Ignore? | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1507 | Insights into Obtaining Grants Offered by the AAAAI Grants Committee | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1508 | Biologics in Aspirin-Exacerbated Respiratory Disease (AERD) | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1510 | Practical Issues of Managing a Patient with Allergic Skin Diseases on Biologics | In-Person Seminar | 2/25/22 | 12:30 pm - 1:30 pm |
| 1521 | The Journal of Allergy and Clinical Immunology (JACI): In Practice Year-in-Review Workshop | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1521 | The Journal of Allergy and Clinical Immunology (JACI): In Practice Year-in-Review Workshop | In-Person Workshop - OD | | |
| 1522 | Idiopathic Angioedema Without Urticaria: State of the Art Approach to Diagnosis and Management | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1522 | Idiopathic Angioedema Without Urticaria: State of the Art Approach to Diagnosis and Management | In-Person Workshop - OD | | |
| 1523 | Proteomic and Lipidomic Approaches to Understanding Asthma | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1523 | Proteomic and Lipidomic Approaches to Understanding Asthma | In-Person Workshop - OD | | |
| 1524 | Genetic Testing 101 | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1524 | Genetic Testing 101 | In-Person Workshop - OD | | |
| 1525 | Local Gastrointestinal Mechanisms of Tolerance and Hypersensitivity | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1525 | Local Gastrointestinal Mechanisms of Tolerance and Hypersensitivity | In-Person Workshop - OD | | |
| 1526 | How and Why to Engage Your Practice with the AAAAI Registry | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1526 | How and Why to Engage Your Practice with the AAAAI Registry | In-Person Workshop - OD | | |
| 1527 | Negotiating Work-Life Integration | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1528 | Food Allergy Quality of Life: Multiple Levels of Analysis for Better Understanding and Care | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1528 | Food Allergy Quality of Life: Multiple Levels of Analysis for Better Understanding and Care | In-Person Workshop - OD | | |
| 1529 | Nasal and Sinus Anatomical Abnormalities and Reading Sinus Computerized Tomography (CT) Scans: What an Allergist Should Know | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1529 | Nasal and Sinus Anatomical Abnormalities and Reading Sinus Computerized Tomography (CT) Scans: What an Allergist Should Know | In-Person Workshop - OD | | |
| 1530 | Severe Asthma Exacerbations: Consequences and Prevention | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1530 | Severe Asthma Exacerbations: Consequences and Prevention | In-Person Workshop - OD | | |
| 1531 | Allied Health: Subcutaneous Immunoglobulin (SCIg): A Therapy in Evolution | In-Person Workshop | 2/25/22 | 12:45 pm - 2:00 pm |
| 1531 | Allied Health: Subcutaneous Immunoglobulin (SCIg): A Therapy in Evolution | In-Person Workshop - OD | | |
| 1601 | Presidential Plenary: Digital Health and Remote Patient Monitoring for Patients with Difficult to Control Asthma | In-Person Plenary | 2/25/22 | 2:15 pm - 3:45 pm |
| 1601 | Presidential Plenary: Digital Health and Remote Patient Monitoring for Patients with Difficult to Control Asthma | In-Person Plenary - OD | | |
| 1801 | Practical Guidance for the Evaluation and Management of Drug Hypersensitivity | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1801 | Practical Guidance for the Evaluation and Management of Drug Hypersensitivity | In-Person Symposium - OD | | |
| 1802 | School Based Asthma Management and COVID-19: Addressing Health Disparities | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1802 | School Based Asthma Management and COVID-19: Addressing Health Disparities | In-Person Symposium - OD | | |
| 1803 | Early Life Environmental Exposures Regulate Host Allergic Immune Responses: Lessons Learned from the Asthma and Allergic Diseases Cooperative Research Centers (AADCRCs) Birth Cohorts | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1803 | Early Life Environmental Exposures Regulate Host Allergic Immune Responses: Lessons Learned from the Asthma and Allergic Diseases Cooperative Research Centers (AADCRCs) Birth Cohorts | In-Person Symposium - OD | | |
| 1804 | New Connections in Sensitization and Tolerance | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1804 | New Connections in Sensitization and Tolerance | In-Person Symposium - OD | | |
| 1805 | Innovative Digital Technologies for Asthma Management: Improving Patient Engagement and Care Delivery | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1805 | Innovative Digital Technologies for Asthma Management: Improving Patient Engagement and Care Delivery | In-Person Symposium - OD | | |
| 1806 | Controversial Topics in Allergen Immunotherapy: Dose Adjustment Strategies after Gaps in Therapy, Severe Asthma, Waiting Times and Epinephrine Autoinjectors | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1806 | Controversial Topics in Allergen Immunotherapy: Dose Adjustment Strategies after Gaps in Therapy, Severe Asthma, Waiting Times and Epinephrine Autoinjectors | In-Person Symposium - OD | | |
| 1807 | Novel Discoveries in Mast Cell Biology | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1807 | Novel Discoveries in Mast Cell Biology | In-Person Symposium - OD | | |
| 1808 | Fungal Diseases of the Respiratory Tract: From Bench to Bedside | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1808 | Fungal Diseases of the Respiratory Tract: From Bench to Bedside | In-Person Symposium - OD | | |
| 1810 | Allied Health Plenary: COVID-19 in 2022: Update for the Health Care Professional | In-Person Symposium | 2/25/22 | 4:00 pm - 5:15 pm |
| 1810 | Allied Health Plenary: COVID-19 in 2022: Update for the Health Care Professional | In-Person Symposium - OD | | |
| 2001 | Not All Anaphylaxis Is The Same: Failure to Recognize Atypical Anaphylaxis Presentation Is Common | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2002 | Emerging and Existing Biomarkers in Asthma Diagnosis and Management | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2004 | Biologic Targeting of Aberrant Immunity in Inflammatory Disease | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2005 | Diagnostics in Cannabis Allergy | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2007 | Using Electronic Medication Monitors to Help Manage Asthma in Your Clinic | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2008 | When the Dust Settles, I Will Get to Me | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2009 | When Should Endoscopic Sinus Surgery Be Considered for Chronic Rhinosinusitis Patients? | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2010 | Recent Advances in Animal Models of Allergic Disease | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2011 | Complex Cases in Eosinophilia: Differential Diagnoses, Evaluation, and Management | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2012 | Love at First Bite: Prevention of Food Allergy in Infants Through Early Introduction | In-Person Seminar | 2/26/22 | 7:00 am - 8:00 am |
| 2021 | Allied Health: Psychosocial Well-Being: Living with Food Allergies | In-Person Workshop | 2/26/22 | 6:45 am - 8:00 am |
| 2021 | Allied Health: Psychosocial Well-Being: Living with Food Allergies | In-Person Workshop - OD | | |
| 2022 | Allied Health: Refractive Urticaria: When Antihistamines Don't Work | In-Person Workshop | 2/26/22 | 6:45 am - 8:00 am |
| 2022 | Allied Health: Refractive Urticaria: When Antihistamines Don't Work | In-Person Workshop - OD | | |
| 2101 | Preparing for the Next Pandemic: From Mechanisms to Vaccines | In-Person Plenary | 2/26/22 | 8:15 am - 9:45 am |
| 2101 | Preparing for the Next Pandemic: From Mechanisms to Vaccines | In-Person Plenary - OD | | |
| 2301 | European Academy of Allergy and Clinical Immunology (EAACI): Immune Modulation for Asthma | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2301 | European Academy of Allergy and Clinical Immunology (EAACI): Immune Modulation for Asthma | In-Person Symposium - OD | | |
| 2302 | Intersection of Genetics, Transcriptomics and Health Disparities in Severe Asthma | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2302 | Intersection of Genetics, Transcriptomics and Health Disparities in Severe Asthma | In-Person Symposium - OD | | |
| 2303 | The Genetics of Primary Immunodeficiency Disorders | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2303 | The Genetics of Primary Immunodeficiency Disorders | In-Person Symposium - OD | | |
| 2304 | Novel Therapies in Food Allergy | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2304 | Novel Therapies in Food Allergy | In-Person Symposium - OD | | |
| 2305 | Rethinking How We Manage Asthma and Allergic Diseases Post- Pandemic | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2305 | Rethinking How We Manage Asthma and Allergic Diseases Post- Pandemic | In-Person Symposium - OD | | |
| 2306 | Racism, Not Race as a Root Cause of Health Disparities | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2306 | Racism, Not Race as a Root Cause of Health Disparities | In-Person Symposium - OD | | |
| 2307 | Allergen Immunotherapy (AIT): New Forms and New Data on Old Variants | In-Person Symposium | 2/26/22 | 10:45 am - 12:00 pm |
| 2307 | Allergen Immunotherapy (AIT): New Forms and New Data on Old Variants | In-Person Symposium - OD | | |
| 2312 | Allied Health: Psychosocial Dynamics with Asthma: Challenges, Vulnerabilities, and Supports | In-Person Workshop | 2/26/22 | 10:45 am - 12:00 pm |
| 2312 | Allied Health: Psychosocial Dynamics with Asthma: Challenges, Vulnerabilities, and Supports | In-Person Workshop - OD | | |
| 2313 | Allied Health: Practical Challenges of Eating Potential Food Allergens: Important Nuggets to Chew on | In-Person Workshop | 2/26/22 | 10:45 am - 12:00 pm |
2405 Career Paths in Allergy and Immunology
In-Person Course2/26/22, 12pm - 1:45pm
12:00 pm - 1:45 pm
| 2411 | Allied Health Professional Assembly Business Meeting and Oral Abstract Session | In-Person Oral Abstract Session | 2/26/22 | 12:15 pm - 1:45 pm |
| 2411 | Allied Health Professional Assembly Business Meeting and Oral Abstract Session | In-Person Oral Abstract Session - OD | | |
| 2501 | Psychosocial Impact of Primary Immunodeficiency Disorders (PID) in Children: Implications for Treatment | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2502 | The Use of Integrative Medicine in the Treatment of Severe Asthma: A Problem-Based Learning (PBL) Case | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2503 | The Latest and Greatest 2019 Update to the American Thoracic Society (ATS)/European Respiratory Society (ERS) Standardization of Spirometry | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2504 | Management of Pediatric Asthma Exacerbations: From Clinic to Emergency Department (ED) and Beyond | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2505 | Recurrent Fever in the Pediatric Patient | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2506 | Single Cell RNAseq: Finding the Needle in the Haystack | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2509 | What Have We Learned from Human Eosinophil "Knockouts"? | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2510 | Before You Call It Mast Cell Activation Syndrome (MCAS): Crucial Steps in Making the Right Diagnosis | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2511 | COVID-19 Associated Pulmonary Aspergillosis | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2512 | Successful Approaches to Eosinophilic Esophagitis (EoE): Long-Term Management Dilemmas | In-Person Seminar | 2/26/22 | 12:30 pm - 1:30 pm |
| 2521 | National Institute of Allergy and Infectious Diseases (NIAID): New Insights Into the Immunoregulation of Atopic Dermatitis | In-Person Symposium | 2/26/22 | 12:30 pm - 1:45 pm |
| 2521 | National Institute of Allergy and Infectious Diseases (NIAID): New Insights Into the Immunoregulation of Atopic Dermatitis | In-Person Symposium - OD | | |
| 2522 | National Institute of Environmental Health Sciences (NIEHS): Molecular Characterization of Allergens and Specific IgE Antibodies | In-Person Symposium | 2/26/22 | 12:30 pm - 1:45 pm |
| 2522 | National Institute of Environmental Health Sciences (NIEHS): Molecular Characterization of Allergens and Specific IgE Antibodies | In-Person Symposium - OD | | |
| 2551 | Evidence Indicates That Patients Taking Beta Blockers Are at Increased Risk for More Serious Anaphylaxis | In-Person Debate | 2/26/22 | 12:30 pm - 1:30 pm |
| 2551 | Evidence Indicates That Patients Taking Beta Blockers Are at Increased Risk for More Serious Anaphylaxis | In-Person Debate - OD | | |
| 2552 | Genetic Testing for All: Putting the Cart Before the Horse? | In-Person Debate | 2/26/22 | 12:30 pm - 1:30 pm |
| 2552 | Genetic Testing for All: Putting the Cart Before the Horse? | In-Person Debate - OD | | |
| 2553 | Patients with Severe Asthma Should Be Permitted to Receive Allergen Immunotherapy | In-Person Debate | 2/26/22 | 12:30 pm - 1:30 pm |
| 2553 | Patients with Severe Asthma Should Be Permitted to Receive Allergen Immunotherapy | In-Person Debate - OD | | |
| 2557 | Interesting Case Workshop | In-Person Interesting Case Workshop | 2/26/22 | 12:30 pm - 1:45 pm |
| 2557 | Interesting Case Workshop | In-Person Interesting Case Workshop - OD | | |
| 2601 | What's New in Drug Allergy | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2602 | Biologic Therapy in Asthma | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2603 | Caring for Patients with Immunodeficiency Disorders During the COVID-19 Pandemic | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2604 | The Intersection of the Environment and the Airways | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2605 | Eosinophilic Esophagitis Inflammation and Clinical Markers and Risk Factors | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2606 | Implementing Guidelines and Promoting Quality Care for Drug Allergy Assessment | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2607 | Rhinitis, Allergens and Immunotherapy | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2608 | Mast Cells and Eosinophils: Heterogeneity, Mechanisms and Therapeutic Approaches | In-Person Oral Abstract Session | 2/26/22 | 2:00 pm - 3:15 pm |
| 2611 | Late Breaking Oral Abstract Session | In-Person Oral Abstract Session (LB) | 2/26/22 | 2:00 pm - 3:15 pm |
| 2701 | The Importance of Diversity in Academia and Team Performance | In-Person Keynote | 2/26/22 | 3:30 pm - 4:30 pm |
| 2701 | The Importance of Diversity in Academia and Team Performance | In-Person Keynote - OD | | |
| 2801 | Hot Topics in Pediatric Allergy and Immunology | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2801 | Hot Topics in Pediatric Allergy and Immunology | In-Person Workshop - OD | | |
| 2802 | The Journal of Allergy and Clinical Immunology (JACI) Year-in-Review Workshop | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2802 | The Journal of Allergy and Clinical Immunology (JACI) Year-in-Review Workshop | In-Person Workshop - OD | | |
| 2803 | Embracing the Continuous Assessment Program (CAP) Together as a Team: Diplomates, ABAI and AAAAI | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2803 | Embracing the Continuous Assessment Program (CAP) Together as a Team: Diplomates, ABAI and AAAAI | In-Person Workshop - OD | | |
| 2804 | Developing a Chemotherapy and Biologics Desensitization Program | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2804 | Developing a Chemotherapy and Biologics Desensitization Program | In-Person Workshop - OD | | |
| 2805 | Problem Based Learning (PBL) Case: An Adult with Severe Uncontrolled Asthma or Is It Asthma/Chronic Obstructive Pulmonary Disease (COPD) Overlap (ACO)? | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2806 | Team Trivia: Learning About Janus Tyrosine Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) Pathways and JAK Inhibitors | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2806 | Team Trivia: Learning About Janus Tyrosine Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) Pathways and JAK Inhibitors | In-Person Workshop - OD | | |
| 2807 | Eosinophilic Gastrointestinal Diseases (EGIDs) Below the Esophagus: Emerging Data on Prevalence, Diagnosis and Treatment Advances | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2807 | Eosinophilic Gastrointestinal Diseases (EGIDs) Below the Esophagus: Emerging Data on Prevalence, Diagnosis and Treatment Advances | In-Person Workshop - OD | | |
| 2808 | Food Allergy on the Threshold | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2808 | Food Allergy on the Threshold | In-Person Workshop - OD | | |
| 2809 | Subcutaneous Immunotherapy: Cross-Reactivity, Extract Stability and Optimum Dosing | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2809 | Subcutaneous Immunotherapy: Cross-Reactivity, Extract Stability and Optimum Dosing | In-Person Workshop - OD | | |
| 2810 | The Bullseye on Prostaglandins: Targeting Asthma Therapy | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2810 | The Bullseye on Prostaglandins: Targeting Asthma Therapy | In-Person Workshop - OD | | |
| 2811 | Allergic Disease Triggered by Cannabis Production and Consumption | In-Person Workshop | 2/26/22 | 4:45 pm - 6:00 pm |
| 2811 | Allergic Disease Triggered by Cannabis Production and Consumption | In-Person Workshop - OD | | |
| 3001 | Air Sampling and Analysis: Current Approaches and Future Developments | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3002 | Aspirin Challenges and Desensitizations for Asthma Control in Aspirin Exacerbated Respiratory Disease (AERD) | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3003 | Problem-Based Learning (PBL): The Importance of Digital Medicine in the Treatment of Severe Asthma/Asthma and Chronic Obstructive Pulmonary Disease (COPD) | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3004 | Characteristics and Management of Pediatric Severe Asthma: An Algorithmic Approach | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3005 | Chronic Granulomatous Disease (CGD) in a New World | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3006 | The Eosinophilic Esophagitis (EoE) Patient in Real-World Practice: Is There a Role for Combination Therapies? | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3007 | The Science Behind New Biomarkers and Diagnostics in Food Allergy | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3009 | Heterogeneity of Eosinophils: Treatment and Management Strategies | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3010 | What to Do with an Abnormal Newborn Screen | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3011 | Contact Dermatitis Through the Ages: Infants to Seniors | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3013 | Ocular Allergies: New Delivery Concepts for Anterior Ocular Delivery of Treatment | In-Person Seminar | 2/27/22 | 7:00 am - 8:00 am |
| 3101 | Anaphylaxis: Novel Mechanisms and Emerging Therapeutic Interventions | In-Person Plenary | 2/27/22 | 8:15 am - 9:45 am |
| 3101 | Anaphylaxis: Novel Mechanisms and Emerging Therapeutic Interventions | In-Person Plenary - OD | | |
| 3301 | World Allergy Forum: Updates on Anaphylaxis from the World Allergy Organization (WAO), Mario Sánchez Borges Memorial Symposium | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3301 | World Allergy Forum: Updates on Anaphylaxis from the World Allergy Organization (WAO), Mario Sánchez Borges Memorial Symposium | In-Person Symposium - OD | | |
| 3302 | A New Age of Allergic Skin Diseases | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3302 | A New Age of Allergic Skin Diseases | In-Person Symposium - OD | | |
| 3303 | Uncovering the Links Between Toxic Stress and Asthma: Implications for Prevention, Disparities and Treatment | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3303 | Uncovering the Links Between Toxic Stress and Asthma: Implications for Prevention, Disparities and Treatment | In-Person Symposium - OD | | |
| 3304 | Mechanisms of Environmental Biohazard Influencers of Allergic Respiratory Disease | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3304 | Mechanisms of Environmental Biohazard Influencers of Allergic Respiratory Disease | In-Person Symposium - OD | | |
| 3305 | Navigating Medical Mistrust in Communities of Color: How the Allergy/Immunology (A/I) Provider Can Help | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3305 | Navigating Medical Mistrust in Communities of Color: How the Allergy/Immunology (A/I) Provider Can Help | In-Person Symposium - OD | | |
| 3306 | Insights Into Th2 Regulation, B Cells, and Antibody Secreting Cells in Inflammation: Research From the 2019 AAAAI Foundation Faculty Development Awardees | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3306 | Insights Into Th2 Regulation, B Cells, and Antibody Secreting Cells in Inflammation: Research From the 2019 AAAAI Foundation Faculty Development Awardees | In-Person Symposium - OD | | |
| 3307 | Regulation and Function of T Cells in Allergic Diseases | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3307 | Regulation and Function of T Cells in Allergic Diseases | In-Person Symposium - OD | | |
| 3308 | Allied Health: Difficult to Control Asthma Across the Ages | In-Person Symposium | 2/27/22 | 10:45 am - 12:00 pm |
| 3308 | Allied Health: Difficult to Control Asthma Across the Ages | In-Person Symposium - OD | | |
| 3501 | Infant Anaphylaxis | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3502 | Telemedicine in Schools for Asthma and Allergy Care | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3503 | Contracting for Adherence: A Special Approach to Adolescents with Severe Asthma | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3504 | Diagnosis and Treatment of Multisystem Inflammatory Syndrome (MIS-C) in Children | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3505 | Asthma/Chronic Obstructive Pulmonary Disease (COPD) Overlap in the Workplace | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3508 | The Unified Airway Disease Hypothesis in Clinical Practice | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3510 | Mast Cells: Living Many Different Lives | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
| 3511 | Oral Immunotherapy (OIT): A Practical Approach | In-Person Seminar | 2/27/22 | 12:30 pm - 1:30 pm |
3520 Asthma Educators Course for Preparation to Become a Certified Educator: Day One
In-Person Course2/27/22, 12:30pm - 6pm
12:30 pm - 6:00 pm
| 3551 | Home-Based Spirometry Is Ready for Prime Time | In-Person Debate | 2/27/22 | 12:30 pm - 1:30 pm |
| 3551 | Home-Based Spirometry Is Ready for Prime Time | In-Person Debate - OD | | |
| 3552 | Electronic Adherence Monitoring Improves Asthma Care | In-Person Debate | 2/27/22 | 12:30 pm - 1:30 pm |
| 3552 | Electronic Adherence Monitoring Improves Asthma Care | In-Person Debate - OD | | |
| 3553 | Sensitization to Environmental Peanut Can Occur Through the Respiratory Tract | In-Person Debate | 2/27/22 | 12:30 pm - 1:30 pm |
| 3553 | Sensitization to Environmental Peanut Can Occur Through the Respiratory Tract | In-Person Debate - OD | | |
| 3557 | Interesting Case Workshop | In-Person Interesting Case Workshop | 2/27/22 | 12:30 pm - 1:45 pm |
| 3557 | Interesting Case Workshop | In-Person Interesting Case Workshop - OD | | |
| 3601 | New Insights in Anaphylaxis | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3602 | Emerging Research in Childhood Asthma | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3603 | Mechanisms of Atopic Disease | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3604 | Immunologic Responses to Environmental Exposures | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3605 | Oral Immunotherapy: Predictors of Success, Real World and Long Term Studies | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3606 | Allergy/Immunology and the COVID-19 Pandemic Response | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3607 | Chronic Rhinosinusitis and Dupilumab | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3608 | New Discoveries on Mechanisms and Endotypes of Asthma | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3609 | Biologic Therapies in Severe and Exacerbation - Prone Asthma | In-Person Oral Abstract Session | 2/27/22 | 2:00 pm - 3:15 pm |
| 3611 | Late Breaking Oral Abstract Session | In-Person Oral Abstract Session (LB) | 2/27/22 | 2:00 pm - 3:15 pm |
| 3701 | ADDA: Biphasic Anaphylaxis: Integrating Best Value Care with Patient Safety | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3701 | ADDA: Biphasic Anaphylaxis: Integrating Best Value Care with Patient Safety | In-Person Interest Section Forum - OD | | |
| 3702 | ADT: The Role of the Maternal Diet During Pregnancy in Asthma and Allergy Prevention | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3702 | ADT: The Role of the Maternal Diet During Pregnancy in Asthma and Allergy Prevention | In-Person Interest Section Forum - OD | | |
| 3703 | BCI: Prevention and Treatment of COVID-19 in Patients with Primary Immune Deficiency Disease (PIDD) | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3703 | BCI: Prevention and Treatment of COVID-19 in Patients with Primary Immune Deficiency Disease (PIDD) | In-Person Interest Section Forum - OD | | |
| 3704 | EORD: Impact of Climate Change on Pollen, Mold and Susceptibility to COVID-19 Infection | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3704 | EORD: Impact of Climate Change on Pollen, Mold and Susceptibility to COVID-19 Infection | In-Person Interest Section Forum - OD | | |
| 3705 | FAED: Is It Sensitization or Clinical Allergy: Novel Food Allergy Diagnostics | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3705 | FAED: Is It Sensitization or Clinical Allergy: Novel Food Allergy Diagnostics | In-Person Interest Section Forum - OD | | |
| 3706 | HEDQ: What the Allergist/Immunologist Needs to Know About Health Disparities | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3706 | HEDQ: What the Allergist/Immunologist Needs to Know About Health Disparities | In-Person Interest Section Forum - OD | | |
| 3707 | IRSO: Rhinitis and Rhinosinusitis: The Role of Type 2 Immune Regulation in COVID-19 Pathogenesis | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3707 | IRSO: Rhinitis and Rhinosinusitis: The Role of Type 2 Immune Regulation in COVID-19 Pathogenesis | In-Person Interest Section Forum - OD | | |
| 3708 | MAAI: The Idiosyncrasies of Severe Asthma Evidence from Cellular, Molecular and Genomic Studies | In-Person Interest Section Forum | 2/27/22 | 3:30 pm - 4:30 pm |
| 3708 | MAAI: The Idiosyncrasies of Severe Asthma Evidence from Cellular, Molecular and Genomic Studies | In-Person Interest Section Forum - OD | | |
| 4002 | The Impact of Chronic Rhinosinusitis on Asthma Outcomes: An Allergist's and Ears, Nose and Throat (ENT's) Perspectives | In-Person Seminar | 2/28/22 | 7:00 am - 8:00 am |
| 4003 | Pediatric Interstitial Lung Disease (ILD) as a Manifestation of Systemic Immunological Disorders | In-Person Seminar | 2/28/22 | 7:00 am - 8:00 am |
| 4005 | The Smart Home Health and Fitness Revolution: Helping Patients Utilize Personal Health Technology | In-Person Seminar | 2/28/22 | 7:00 am - 8:00 am |
| 4006 | Carbohydrate Epitopes as Targets for Immunoglobulin E (IgE) Antibodies: New Developments the Allergist Should Know | In-Person Seminar | 2/28/22 | 7:00 am - 8:00 am |
| 4007 | Environmental Justice and the Pursuit of Health Equity | In-Person Seminar | 2/28/22 | 7:00 am - 8:00 am |
| 4008 | Asthma Management in the Age of COVID-19 | In-Person Seminar | 2/28/22 | 7:00 am - 8:00 am |
4020 Asthma Educators Course for Preparation to Become a Certified Educator: Day Two
In-Person Course2/28/22, 8am - 4:15pm
8:00 am - 4:15 pm
| 4101 | An Ounce of Prevention | In-Person Plenary | 2/28/22 | 8:15 am - 9:45 am |
| 4101 | An Ounce of Prevention | In-Person Plenary - OD | | |
| 4301 | Schools and Difficult to Control Asthma | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4301 | Schools and Difficult to Control Asthma | In-Person Symposium - OD | | |
| 4302 | The Evolving Impact of Respiratory Viruses on Asthma | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4302 | The Evolving Impact of Respiratory Viruses on Asthma | In-Person Symposium - OD | | |
| 4303 | A Multidisciplinary Approach to Refractory Chronic Cough | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4303 | A Multidisciplinary Approach to Refractory Chronic Cough | In-Person Symposium - OD | | |
| 4304 | Autoinflammatory Syndromes: How and When to Do a Diagnostic Work Up and Current Treatment Options | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4304 | Autoinflammatory Syndromes: How and When to Do a Diagnostic Work Up and Current Treatment Options | In-Person Symposium - OD | | |
| 4305 | Mitigating the Allergen Exposures Causing Uncontrolled Pediatric Asthma | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4305 | Mitigating the Allergen Exposures Causing Uncontrolled Pediatric Asthma | In-Person Symposium - OD | | |
| 4306 | Nature versus Nurture: Genetic and Environmental Factors Implicated in the Pathogenesis of Eosinophilic Esophagitis (EoE) | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4306 | Nature versus Nurture: Genetic and Environmental Factors Implicated in the Pathogenesis of Eosinophilic Esophagitis (EoE) | In-Person Symposium - OD | | |
| 4307 | Shared Decision Making (SDM): Recent Advances for Allergy/Immunology Patients | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4307 | Shared Decision Making (SDM): Recent Advances for Allergy/Immunology Patients | In-Person Symposium - OD | | |
| 4308 | Potential Untapped Targets in Severe Asthma | In-Person Symposium | 2/28/22 | 10:45 am - 12:00 pm |
| 4308 | Potential Untapped Targets in Severe Asthma | In-Person Symposium - OD | | |
| 4601 | Best of Allergic Skin Disease 2022 | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4602 | Asthma Pathogenesis | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4603 | Primary Immunodeficiency Disorders | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4604 | Food Allergy: From Early Life to Therapy | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4605 | Biologic Mechanisms and Rhinitis | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4606 | Host-Microbiome Interactions in Allergic Diseases | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4607 | Insights to the Development and Management of Difficult to Control Asthma | In-Person Oral Abstract Session | 2/28/22 | 2:00 pm - 3:15 pm |
| 4701 | Improving the Pediatric Asthma Visit: Tools for Obtaining a History, Correct Diagnosis and Treatment Plan | In-Person Workshop | 2/28/22 | 3:30 pm - 4:45 pm |
| 4701 | Improving the Pediatric Asthma Visit: Tools for Obtaining a History, Correct Diagnosis and Treatment Plan | In-Person Workshop - OD | | |
| 4702 | Treatment Algorithms for Difficult to Control Asthma in Diverse Populations | In-Person Workshop | 2/28/22 | 3:30 pm - 4:45 pm |
| 4702 | Treatment Algorithms for Difficult to Control Asthma in Diverse Populations | In-Person Workshop - OD | | |
| 4704 | Contributions of Eosinophils to Health and Allergy | In-Person Workshop | 2/28/22 | 3:30 pm - 4:45 pm |
| 4704 | Contributions of Eosinophils to Health and Allergy | In-Person Workshop - OD | | |
| 4711 | Monoclonal Antibodies (MABS) for Kids: Picking the Right Biologic Therapy for Children with Severe Asthma | In-Person Seminar | 2/28/22 | 3:30 pm - 4:30 pm |
| 4712 | Component Resolved Diagnostics in Pet Allergies | In-Person Seminar | 2/28/22 | 3:30 pm - 4:30 pm |
| 5001 | Microbial Contribution to Asthma Pathogenesis | Pre-Recorded Course | | |
| 5002 | The Impact of Air Pollution and Climate Change in Viral, Fungal and Bacterial Airways Infection | Pre-Recorded Course | | |
| 5003 | Asthma: The Basics of Medical Education Strategies from Instructional Design to Disparities | Pre-Recorded Course | | |
| 5004 | Workforce Challenges in Allergy/Immunology | Pre-Recorded Course | | |
| 5101 | A Bench to Bedside View of Drug Hypersensitivity | Pre-Recorded Symposium | | |
| 5102 | Stay Current with Drug Hypersensitivity | Pre-Recorded Symposium | | |
| 5103 | “Is it Just Me or Does My Throat Feel Tight?”: Considering Mimickers of Anaphylaxis | Pre-Recorded Symposium | | |
| 5104 | Defining and Managing Anaphylaxis in 2022 | Pre-Recorded Symposium | | |
| 5105 | What Does Anaphylaxis Look Like in Infants and Toddlers? | Pre-Recorded Symposium | | |
| 5106 | Are You What You Eat in Atopy and Autoimmunity? | Pre-Recorded Symposium | | |
| 5107 | Beyond Short-Acting Bronchodilator (SABA): Next-Line and Adjunct Treatments for Exercise-Induced Bronchoconstriction (EIB) | Pre-Recorded Symposium | | |
| 5108 | Managing Metabolic Dysfunction in Asthma: An Opportunity for Improvement | Pre-Recorded Symposium | | |
| 5109 | Childhood Asthma: How Does it Begin? Can We Prevent it? | Pre-Recorded Symposium | | |
| 5110 | Is Severe Asthma Management Different Across the Age Spectrum? | Pre-Recorded Symposium | | |
| 5111 | Biologic Selection in Patients with Asthma, Allergic Rhinitis and Atopic Dermatitis | Pre-Recorded Symposium | | |
| 5112 | Recognizing and Treating Interstitial Lung Disease in Primary Immunodeficiency | Pre-Recorded Symposium | | |
| 5113 | Immune Pathway Targeting with Biologics for the Treatment of Inflammatory Conditions | Pre-Recorded Symposium | | |
| 5114 | The Role of the Immune System in Severe COVID-19 Infections | Pre-Recorded Symposium | | |
| 5115 | Hot New Defects in Clinical Immunology | Pre-Recorded Symposium | | |
| 5116 | Improving Adherence and Outcomes for the Difficult-to-Treat Asthma Patient | Pre-Recorded Symposium | | |
| 5117 | Harnessing Available Data in Answering Important Questions About Allergic/Immunologic Diseases | Pre-Recorded Symposium | | |
| 5118 | Joint Task Force on Practice Parameters (JTFPP) Guidelines: Practice Parameters, Guidelines, and Updates | Pre-Recorded Symposium | | |
| 5119 | Partnering with Federally Qualified Health Centers (FQHCs) to Advance Research, Education and Specialty Care in Allergy/Immunology for Underserved Patients with Uncontrolled Asthma | Pre-Recorded Symposium | | |
| 5120 | Health Disparity and its Devastating Impact on Patients Who Have Combined Chronic Airways Disease: Chronic Rhinosinusitis (CRS) and Asthma | Pre-Recorded Symposium | | |
| 5121 | COVID-19 and its Link to Upper Airway Inflammation | Pre-Recorded Symposium | | |
| 5122 | Refractory Asthma: Can They Smell the Roses? | Pre-Recorded Symposium | | |
| 5123 | Evolving Choosing Wisely: Identifying Vulnerabilities in Allergy/Immunology Care | Pre-Recorded Symposium | | |
| 5124 | Structural Racism and COVID-19: Lessons Learned About Achieving Racial Equity in Research, Vaccine Uptake and Asthma | Pre-Recorded Symposium | | |
| 5125 | Personalized Medicine and Rhinitis | Pre-Recorded Symposium | | |
| 5126 | Allergen Diagnostics: Component Testing for Respiratory Allergens | Pre-Recorded Symposium | | |
| 5127 | Diagnosis in Allergic Respiratory Diseases: Beyond Detection of Immunoglobulin E (IgE) | Pre-Recorded Symposium | | |
| 5128 | Non-Surgical Treatment for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Pre-Recorded Symposium | | |
| 5129 | Updates from the Bench: Novel Insights into The Pathophysiology of Chronic Rhinosinusitis (CRS) and Potential Applications for Clinical Therapies | Pre-Recorded Symposium | | |
| 5130 | Endotypes and Phenotypic Implications of Chronic Rhinosinusitis (CRS) | Pre-Recorded Symposium | | |
| 5131 | Multidisciplinary Approach to the Management of Chronic Rhinosinusitis | Pre-Recorded Symposium | | |
| 5132 | Human Group 2 Innate Lymphoid Cells (ILC2s): Rapidly Moving into Clinical Relevance | Pre-Recorded Symposium | | |
| 5133 | Allied Health: The Challenges of Food Challenges: the Good, the Bad and the Ugly | Pre-Recorded Symposium | | |
| 5134 | Allied Health: Research Studies and Oral Immunotherapy (OIT): One Size Does Not Fit All | Pre-Recorded Symposium | | |
| 5135 | Allied Health: Asthma and Obesity | Pre-Recorded Symposium | | |
| 5136 | Allied Health: Food Insecurity in the Food Allergic Population | Pre-Recorded Symposium | | |
| 5137 | Allied Health: Immunoglobulin E (IgE) or Not Immunoglobulin E (IgE): This is the Dilemma - Emerging Food Allergies | Pre-Recorded Symposium | | |
| 5139 | Allied Health: You Down with Regulatory, Yeah You Know Me | Pre-Recorded Symposium | | |
| 5140 | Allied Health: Let the Babies Eat! How Healthcare Professionals Can Motivate Parents to Prevent Food Allergies | Pre-Recorded Symposium | | |
| 5141 | Allied Health: Oral Immunotherapy to Foods: It Takes a Village | Pre-Recorded Symposium | | |
| 5142 | Allied Health: Demystifying Epinephrine | Pre-Recorded Symposium | | |
| 5143 | Recent Advancements in the Mechanisms of Chronic Rhinosinusitis (CRS) | Pre-Recorded Symposium | | |
| 5144 | COVID-19 and Allergen Immunotherapy | Pre-Recorded Symposium | | |
| 5201 | Problems in the Diagnosis and Management of Insect Allergy | Pre-Recorded Workshop | | |
| 5202 | Asthma Exacerbations in Childhood: Risk Factors, Consequences, Causes and Ways to Alter Them | Pre-Recorded Workshop | | |
| 5203 | Viral Vaccines for Asthma | Pre-Recorded Workshop | | |
| 5204 | The Know-How of Immunoglobulin Replacement Therapy and Management | Pre-Recorded Workshop | | |
| 5205 | Antibody Deficiency Syndromes and Lung Disease | Pre-Recorded Workshop | | |
| 5206 | Diagnosis and Management of Secondary Hypogammaglobulinemia | Pre-Recorded Workshop | | |
| 5207 | Vaccination and the Allergist/Immunologist | Pre-Recorded Workshop | | |
| 5208 | The Role of Fungi in Difficult to Control Asthma | Pre-Recorded Workshop | | |
| 5209 | Dynamic Interactions of Pollen and the Environment with Allergic and Respiratory Disease | Pre-Recorded Workshop | | |
| 5210 | How an Engaging Allergy/Immunology Elective Grows Your Practice and Our Specialty | Pre-Recorded Workshop | | |
| 5211 | AllergoOncology: The Link Between Immunology, Allergy and Oncology | Pre-Recorded Workshop | | |
| 5212 | Beyond Immunoglobulin E (IgE): Reconsidering Mechanisms of Mast Cell Activation in Clinical Allergy | Pre-Recorded Workshop | | |
| 5213 | New Insights into the Immune Mechanisms of Severe Asthma | Pre-Recorded Workshop | | |
| 5214 | Novel Aspects of Airway Inflammation in Response to Environmental Challenges | Pre-Recorded Workshop | | |
| 5215 | Thinking Beyond Lymphocytes in Asthma: Platelets as Immune Cells | Pre-Recorded Workshop | | |
| 5216 | The Origin and Fate of Immunoglobulin E (IgE) - Switched B Cells | Pre-Recorded Workshop | | |
| 5217 | Allied Health: Navigating Access to Biologics: Medical Benefit, Pharmacy Benefit and Copay Assistance | Pre-Recorded Workshop | | |
| 5218 | Allied Health: Telemedicine Tips for Advanced Practice Providers | Pre-Recorded Workshop | | |
| 5219 | Update from the U.S. Food and Drug Administration | Pre-Recorded Workshop | | |
| 5220 | National Heart, Lung, and Blood Institute (NHLBI): Innovation in School-Based Asthma Care | Pre-Recorded Symposium | | |
| 5301 | Treatment of Aspirin Exacerbated Respiratory Disease (AERD): Surgery and Aspirin (ASA) Desensitization Should Be the Standard of Care | Pre-Recorded Debate | | |
| 5302 | Oral Food Challenges in Infants Are Necessary | Pre-Recorded Debate | | |
| 5303 | Eosinophils Are Important in Chronic Rhinosinusitis Pathogenesis | Pre-Recorded Debate | | |